0001656472-24-000021 | 10-K | XBRL Viewer

Print Document View Excel Document

Commitments and Contingencies - R&D Commitments (Details) - USD ($) $ in Thousands			12 Months Ended
	Feb. 18, 2019	Sep. 04, 2018	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 17, 2018
Common Shares
Long-term Purchase Commitment [Line Items]
Share issuance pursuant to research and development milestone (in shares)				4,157,888	2,934,980
Ginkgo \| Common Shares
Long-term Purchase Commitment [Line Items]
Share issuance pursuant to research and development milestone (in shares)			4,157,888	2,934,980		0
Ginkgo \| Research and Development Arrangement
Long-term Purchase Commitment [Line Items]
Common shares issuable (up to) (in shares)		14,674,903
Common shares issuable, value assigned							$ 100,000
Payments subject to milestones		$ 22,000
Altria Ventures \| Consulting Services Arrangement
Long-term Purchase Commitment [Line Items]
Monthly fee, percentage of direct and indirect service costs	105.00%

Related Party Transactions - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 08, 2019
Related Party Transaction [Line Items]
Accounts payable	$ 12,130,000	$ 11,163,000
Related Party
Related Party Transaction [Line Items]
Carrying value of held for sale assets sold	332,000
Proceeds from sale of assets	761,000
Gain on sale of assets	436,000
Related Party \| Consulting Services
Related Party Transaction [Line Items]
Accounts payable	0	0
Related party transaction amount	0	0	$ 436,000
Related Party \| Cannabis Purchases
Related Party Transaction [Line Items]
Accounts payable	2,267,000	2,519,000
Purchases	21,335,000	18,144,000	$ 4,820,000
Related Party \| Cannabis Germplasm Supply Agreement
Related Party Transaction [Line Items]
Related party transaction amount	1,114,000
Related Party \| Manufacturing Services
Related Party Transaction [Line Items]
Accounts payable	11,000
Purchases	42,000
Immediate Family Member of Management or Principal Owner \| Manufacturing Services
Related Party Transaction [Line Items]
Accounts payable	28,000	0
Purchases	$ 2,310,000	$ 645,000
Cronos Group, Inc. \| Altria Group, Inc.
Related Party Transaction [Line Items]
Ownership interest	41.10%			45.00%
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest	50.00%	50.00%

Inventory, net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 4,795	$ 7,421
Work-in-progress	10,593	15,646
Finished goods	14,819	13,503
Supplies and consumables	288	989
Total	$ 30,495	$ 37,559

Investments

12 Months Ended

Dec. 31, 2023

Equity Method Investments and Joint Ventures [Abstract]

Investments

(a)Variable interest entities and investments in equity method investments, net

The Company holds variable interests in Cronos Growing Company Inc. (“Cronos GrowCo”) and Cannasoul Lab Services Ltd. (“CLS”). The Company’s investment in Cronos GrowCo is exposed to economic variability based on the entity’s performance; however, the Company does not consolidate the entity as it does not have the power to direct the activities that most significantly impact the entity’s economic performance. Thus, the Company is not considered the primary beneficiary of the entity. The investment in Cronos GrowCo is accounted for as an equity method investment classified as “Equity method investments, net” in the consolidated balance sheets.

Cronos GrowCo

Cronos GrowCo is a joint venture incorporated under the Canada Business Corporations Act on June 14, 2018, with the objective of cultivating and commercializing cannabis and cannabis products. Cronos GrowCo’s economic performance is driven by the day-to-day operations of Cronos GrowCo, which are controlled by 2645485 Ontario Inc. (“Mucci”), the Company’s joint venture partner.

During the year ended December 31, 2021, the Company concluded that lower than expected sales forecasts combined with the increase to the aggregate principal amount of the GrowCo Credit Facility (as defined below) were indicators of impairment for the Company’s equity method investment in Cronos GrowCo. Accordingly, the Company performed a quantitative impairment assessment in the third quarter of 2021 to compare the fair value of the investment in Cronos GrowCo to its carrying amount. The fair value was estimated using the discounted cash flow method. Significant inputs included discount rate, growth rates, and cash flow projections. As a result of this analysis, the Company concluded that as of September 30, 2021, the estimated fair value was higher than the carrying amount and no impairment charges were recorded. There were no such indicators of impairment present for the years ended December 31, 2023 and 2022.

CLS

CLS is a wholly owned subsidiary of Cannasoul Analytics Ltd., incorporated with the purpose of establishing a commercial cannabis analytical testing laboratory located on the premises of Cronos Israel (the “Cannasoul Collaboration”). Cronos Israel agreed to advance up to ILS 8,297 ($2,664) by a non-recourse loan (the “Cannasoul Collaboration Loan”) to CLS over a period of two years from April 1, 2020 for the capital and operating expenditures of the laboratory. The loan bears interest at 3.5% annually. Cronos Israel will receive 70% of the profits of the laboratory until such time as it has recovered 150% of the amounts advanced to CLS, after which time it will receive 50% of the laboratory profits. As a result, the Company is exposed to economic variability from CLS’s performance. The Company does not consolidate CLS as it does not have the power to direct the activities that most significantly impact the entity’s economic performance; thus, the Company is not considered the primary beneficiary of the entity. The carrying amount of the non-recourse loan is recorded under loans receivable and the full loan amount, ILS 8,297, represents the Company’s maximum potential exposure to losses through the Cannasoul Collaboration. See Note 5 “Loans Receivable, net” for further information regarding loans receivable.

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2023		2022

Cronos GrowCo	50%	$	19,488	$	18,755

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2023		2022		2021
Vitura(i)	N/A		N/A		$	(48)
Cronos GrowCo	1,583		3,114		(2,518)
Natuera(ii)	N/A		N/A		(3,747)
	$	1,583	$	3,114	$	(6,313)

(i)As of December 31, 2023 and December 31, 2022, the Company held a 9.6% and 9.9% ownership interest, respectively, in Vitura, and Vitura was no longer considered an equity-method investment. As of and up to December 16, 2021, the Company held a 31% ownership interest in Vitura and was considered an equity-method investment.

(ii)As of December 31, 2021, the combination of the Company’s share of accumulated net losses and impairment charges was in excess of its equity investment in Natuera, and the net book value of the investment was zero.

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2023		2022		2021
Current assets	$	19,600	$	21,158	$	5,660
Non-current assets	99,227		104,227		125,777
Current liabilities	9,707		5,593		13,457
Non-current liabilities	64,814		73,779		81,594


	Year ended December 31,
	2023		2022		2021
Revenue	$	40,604	$	39,110	$	8,186
Gross profit	21,565		24,379		(5,059)
Net income (loss)	3,051		6,569		(12,603)

The following is a summary of the maximum exposure to loss from the Company’s investments in equity method investments:


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss

Cronos GrowCo	50%	$	44,306	$	19,488

Balance as of December 31, 2023		$	44,306	$	19,488


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss
Cronos GrowCo	50%	$	46,013	$	18,755


Balance as of December 31, 2022		$	46,013	$	18,755

The Company’s maximum exposure to loss is equal to the carrying amount of the investment.

(b)Other investments

Other investments consist of investments in common shares and options of two companies in the cannabis industry.

PharmaCann Option

On June 14, 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The option exercise will be based upon various factors, including the status of U.S. federal cannabis legalization, as well as regulatory approvals, including in the states where PharmaCann operates that may be required upon exercise. The Company has deemed its influence in PharmaCann to be non-significant. The PharmaCann Option is classified as an investment in an equity security without a readily determinable fair value. The Company measures the PharmaCann Option at cost less accumulated impairment charges, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The PharmaCann Option is reported as Other investments on the consolidated balance sheet for the periods ended December 31, 2023 and 2022.

As of December 31, 2021, the Company performed an assessment on the existence of impairment indicators on the PharmaCann Option and noted no indicators of impairment existed. As such, no impairment loss on the investment was recorded during the year ended December 31, 2021.

On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of December 31, 2023 and 2022, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 5.9% and 6.3%, respectively. Under the terms of the Company’s investment in PharmaCann, the Company’s rights to nominate an observer or a director to the PharmaCann board of directors could be lost if the Company’s ownership drops below 6% on a fully diluted basis and it sells or transfer all or any portion of the option (subject to certain exceptions). The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option.

During the first, third and fourth quarters of 2022, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the income approach and the market approach. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, cash flow projections, and the expectation of federal rescheduling and individual state legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of these analyses, the Company recorded non-cash impairment charges of $11,238, $28,972 and $21,182 in the first, third and fourth quarters of 2022, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the consolidated statements of net loss and comprehensive loss.

During the fourth quarter of 2023, the Company identified adverse forecast changes in the financial performance of PharmaCann as an indicator of impairment related to the PharmaCann Option and conducted an analysis comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the income approach and the market approach. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, cash flow projections, and the expectation of federal rescheduling and individual state legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of this analysis, the Company recorded a non-cash impairment charge of $23,350 in the fourth quarter of 2023 as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the consolidated statements of net loss and comprehensive loss for the year ended December 31, 2023.

Vitura (formerly known as Cronos Australia)

On September 14, 2021, Cronos Australia (now, Vitura Health Limited) entered into a merger agreement to acquire 100% of the issued shares of CDA Health Pty Ltd, an Australian medicinal cannabis company, subject to customary closing conditions, including shareholder approval (the “Cronos Australia Merger”). The Cronos Australia Merger closed on December 16, 2021. In connection with the closing of the Cronos Australia Merger, all advances made under the Company’s A$1,500 unsecured loan to Cronos Australia, plus accrued interest and certain royalties payable, were converted into ordinary shares of Cronos Australia. In addition, the Company’s ownership interest in Cronos Australia decreased to approximately 10% and the Company’s number of Cronos Australia board seats was reduced from two to zero. On November 29, 2022, the shareholders of Cronos Australia approved the proposal to change the name of the company to “Vitura Health Limited” (the “CAU Name Change”). On December 2, 2022, in connection with the CAU Name Change, Vitura and the Company mutually agreed to terminate the intellectual property license that granted Vitura the right to use certain intellectual property of the Company, including, but not limited to, the “Cronos” name and the PEACE NATURALS® brand. The reduction in ownership interest and loss of all board seats constituted a loss of significant influence and resulted in a reclassification on the consolidated balance sheet from investments in equity method investments using the equity method of accounting to other investments using the fair value method of accounting, with unrealized holding gains and losses included in net loss on the consolidated statements of net loss and comprehensive loss.

The Company recorded a loss on revaluation of other investments of $12,096 for the year ended December 31, 2023, and a gain on revaluation of other investments of $14,739 for the year ended December 31, 2022, included in the gain on revaluation of financial instruments on the statements of net loss and comprehensive loss. The Company’s investment in Vitura was $9,601 and $21,993 as of December 31, 2023 and 2022, respectively, and is included in other investments on the consolidated balance sheets.

The following table summarizes the Company’s other investments activity:


	As of January 1, 2023		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2023
PharmaCann	$	49,000	$	—	$	(23,350)	$	—	$	25,650
Vitura	21,993		(12,096)		—		(296)		9,601
	$	70,993	$	(12,096)	$	(23,350)	$	(296)	$	35,251


	As of January 1, 2022		Unrealized gain		Impairment charges		Foreign exchange effect		As of December 31, 2022
PharmaCann	$	110,392	$	—	$	(61,392)	$	—	$	49,000
Vitura	8,000		14,739		—		(746)		21,993
	$	118,392	$	14,739	$	(61,392)	$	(746)	$	70,993

Discontinued Operations - Restructuring Activity (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 0	$ 0
Expenses	523	1,788	$ 0
Payments/Write-offs	(523)	(1,788)
Restructuring Reserve, Ending Balance	0	0	0
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0	0
Expenses	431	1,788
Payments/Write-offs	(431)	(1,788)
Restructuring Reserve, Ending Balance	0	0	$ 0
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Expenses	92
Payments/Write-offs	(92)
Restructuring Reserve, Ending Balance	$ 0	$ 0

Restructuring - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,524	$ 3,545	$ 0
Inventory write-down	805	0	$ 11,961
Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 3,545
Inventory write-down	$ 805

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Loss per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Basic loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$ (69,849)	$ (155,178)	$ (126,982)
Weighted-average number of common shares outstanding for computation for basic earnings per share (in shares)	380,964,739	376,961,797	370,390,965
Weighted-average number of common shares outstanding from computation for diluted earnings per share (in shares)	380,964,739	376,961,797	370,390,965
Basic loss from continuing operations per share (in dollars per share)	$ (0.18)	$ (0.41)	$ (0.34)
Diluted loss per share from continuing operations (in dollars per share)	$ (0.18)	$ (0.41)	$ (0.34)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ (4,114)	$ (13,556)	$ (269,125)
Weighted-average number of common shares outstanding from computation for basic earnings per share (in shares)	380,964,739	376,961,797	370,390,965
Basic loss from discontinued operations per share (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.73)
Diluted loss from discontinued operations per share (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.73)
Total anti-dilutive securities (in shares)	25,426,119	112,612,579	125,195,001

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 2,505	$ 3,451	$ 11,144
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	67	183	971
Depreciation expense on right-of-use assets	198	865	548
Restructuring costs	$ 523	$ 1,788	$ 0

Income Taxes - Schedule of Income (Loss) before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (73,669)	$ (121,003)	$ (128,510)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Financial Instruments - Liquidity Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk [Line Items]
Accounts payable, trade, current	$ 8,887	$ 8,599
Accounts Payable \| Supplier Concentration Risk \| One Vendor
Concentration Risk [Line Items]
Concentration risk, percentage	26.00%	27.00%

Derivative Liabilities - Narrative (Details) $ in Thousands	Mar. 08, 2019 warrant $ / shares shares	Dec. 31, 2023 shares	Dec. 31, 2022 USD ($)
Altria Group, Inc. \| Cronos Group, Inc.
Derivative [Line Items]
Ownership interest	45.00%	41.10%
Balance held (in shares) \| shares		156,573,537
Altria Investment
Derivative [Line Items]
Shares issued (in shares) \| shares	149,831,154
Altria Warrant
Derivative [Line Items]
Number of warrants issued \| warrant	1
Derivative liability \| $			$ 0
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Top-up Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Exercise price, volume-weighted average price, measurement period	10 days
Exercise price, volume-weighted average price, measurement period, days preceding exercise	10 days

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year amounts have been reclassified to conform to the current year presentation of our consolidated financial statements, which includes discontinued operations. These reclassifications had no effect on reported results of operations and ending shareholders’ equity.

Basis of consolidation

Basis of consolidationThe accompanying consolidated financial statements include the accounts of the Company, and all entities in which the Company has a controlling voting interest or is the primary beneficiary of a variable interest as of and for the reporting periods. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. If an entity is not deemed to be a VIE, the Company consolidates the entity if the Company has a controlling voting interest. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. Investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not have control, are accounted for under the equity method of accounting.

In the consolidated statements of net loss and comprehensive loss, net loss and comprehensive loss are attributed to the equity holders of the Company and to the non-controlling interests. Non-controlling interests in the equity of Cronos Israel are presented separately in the shareholders’ equity section of the consolidated balance sheets and consolidated statements of shareholders’ equity. All intercompany transactions and balances are eliminated upon consolidation.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include, among other things, valuation of derivative liabilities, expected credit losses on long-term financial assets, impairment losses on goodwill and indefinite-lived intangible assets, impairment losses on long-lived assets,

inventory write-downs, share-bared payments, valuation allowance on deferred income tax assets and uncertain tax liabilities. Actual results could differ from those estimates.

Cash and cash equivalents and short-term investments

Cash and cash equivalents are comprised of cash and highly liquid short-term investments that are readily convertible into known amounts of cash, generally with original maturities of three months or less. Cash and cash equivalents include amounts held in dollars, C$, and ILS and security deposits. Short-term investments consist of debt securities that (i) generally have original maturities of greater than three months and (ii) the Company has the ability to convert into cash within one year.

Short-term investments are classified as held-to-maturity and recorded at cost. Interest earned on short-term investments is recorded in other receivables on the consolidated balance sheets and interest income, net on the consolidated statements of net loss and comprehensive loss. Cash inflows and outflows related to the purchase and maturity of short-term investments are classified as investing activities in the Company’s consolidated statements of cash flows.

Inventory

Inventory is comprised of raw materials, finished goods and work-in-progress, such as pre-harvested cannabis plants, dried flower, by-products to be extracted, cannabis extracts and by-products, dry cannabis and cannabis extract containers, and boxes. When the Company cultivated cannabis, costs capitalized into inventory until the time of harvest included, but were not limited to, labor, utilities, nutrition and irrigation.

Inventory is stated at the lower of cost and net realizable value, determined using weighted average cost. Cost includes expenditures directly related to manufacturing and distribution of the products. Primary costs include consumables (insect control, fertilizers, soil), packaging, shipping, direct labor, contract manufacturer fees, overhead, supplies and small tools, and the depreciation of manufacturing equipment and production facilities determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, rent, utilities, security, and property taxes. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment to measure inventory at the lower of cost and net realizable value. Factors considered in the determination of net realizable value include slow-moving or non-marketable products.

Variable interest entities

A variable interest entity is an entity having either a total equity investment that is insufficient to finance its activities without additional subordinated financial support or equity investors at risk that lack the ability to control the entity’s activities. Variable interests are investments or other interests that will absorb portions of a VIE’s expected losses or receive portions of the VIE’s expected residual returns. The Company evaluates whether it is the primary beneficiary of each VIE it identifies on a periodic basis and considers the impact of any reconsideration events. The primary beneficiary is the party that has both the power to direct the activities that most significantly impact the VIE and holds a variable interest that could potentially be significant to the VIE. To make this determination, the Company considers both quantitative and qualitative factors regarding the nature, size and form of its involvement with the VIE. The Company consolidates a VIE when it is determined that it is the primary beneficiary of the VIE.

Equity method investments

The Company accounts for investments in companies over which it has the ability to exercise significant influence but does not hold a controlling financial interest using the equity method. Under the equity method, the Company records its proportionate share of income or loss in share of income (loss) from equity method investments within the consolidated statements of net loss and comprehensive loss. Cash payments to equity method investees such as additional investments or expenses incurred on behalf of investees, as well as income earned and payments from equity method investees such as dividends and distributions are recorded as adjustments to investment balances. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized in one period cannot be reversed in subsequent periods.

Other investments

Other investments include common stock and options in third-party entities in which the Company’s influence is deemed non-significant. The Company holds other investments with and without readily determinable fair values. Other investments with readily determinable fair values are recorded using the fair value method of accounting as of period-end on the consolidated balance sheets. Other investments without readily determinable fair values are recorded using the cost method of accounting on the consolidated balance sheets. Other investments without readily determinable fair values are assessed for observable price changes and other than temporary impairment on a periodic basis. Changes in the reported value of other investments are reported in the consolidated statements of net loss and comprehensive loss.

Property, plant & equipment

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

5 to 7 years

Furniture and fixtures

5 years

When assets are disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized. Maintenance and repairs are charged to expense as incurred. Significant expenditures, which increase productivity or extend the useful life of the asset, are capitalized.

Available for use is defined as the point at which the related property, plant and equipment is operational, including the possession of any requisite licenses. Depreciation commences at the point the assets are available for use.

Definite life intangible assets

Definite-lived intangible assets

Intangible assets are recorded at cost less any accumulated amortization and accumulated impairment losses. Intangible assets acquired through a business combination are measured at fair value at the acquisition date.

The Company capitalizes certain costs incurred in connection with its enterprise software, which include external direct costs of materials and services consumed in developing or obtaining internal-use software and payroll and payroll-related costs for employees who are directly associated with and who devote time to the development of the software for the function intended. All other costs are expensed as incurred.

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities

(i) The preliminary licenses granted to Kibbutz Gan Shmuel (the Cronos Israel joint venture partner) by the Medical Cannabis Unit of the Israeli Ministry of Health in early 2017 (the “Israeli codes”) were transferred by non-controlling interests to Cronos Israel in exchange for equity interests in the Cronos Israel entities specified above.

Amortization begins when assets become available for use. The estimated useful life, amortization method, and rate are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Intangible assets originating from the strategic partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) are accounted for in accordance with the acquisition method of accounting. Equity interests issued in exchange for an asset are initially recognized and measured at the date of acquisition at fair value. We estimate fair value using the relief-from-royalty method and key assumptions include the discount rate and estimated life. Definite-lived intangible assets, including intangible assets originating from the Ginkgo Strategic Partnership, are subject to amortization and reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value has been reduced to less than its carrying amount.

Accrued liabilities

Accrued payroll and related expenses include salaries and wages, bonuses, and other related payroll expenses associated with the Company’s employees. Accrued professional fees include fees for legal expenses, litigation, consulting, marketing, and other related expenses. Accrued taxes include sales, excise and other taxes owed. Other accrued expenses include the fair value of deferred share units outstanding to directors and other general expenses.

Leases

The Company enters into leases in the normal course of business, primarily for the land-use rights, office premises, and equipment used in the production of its products. At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company performs an analysis over the classification of the lease agreement as either an operating lease or finance lease.

A right-of-use asset and the related lease obligation associated with the lease are recorded at the inception of the lease. The right-of-use asset’s recorded amount is based on the present value of future lease payments over the lease term at the commencement date plus any initial direct costs incurred. If the rate implicit in the lease is not readily determinable for the Company’s operating leases, an incremental borrowing rate is generally used based on information available at the lease commencement date to determine the present value of future lease payments. Subsequent changes to these lease payments due to rate updates are recorded as lease expense in the period incurred. Leases with a term of 12 months or less are not recorded on the balance sheet as a lease.

The right-of-use asset is subject to impairment testing whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company.

The Company’s lease agreements generally exclude non-lease components. As a result, non-lease components are accounted for separately for all classes of assets and expensed as incurred. In addition, the Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of net loss and comprehensive loss.

Derivative liabilities

For financial instruments classified as derivatives that are not designated as hedging instruments or do not qualify for hedge accounting, changes in fair value are recorded in the consolidated statements of net loss and comprehensive loss each period. The Company does not enter into or hold derivative financial instruments for trading or speculative purposes. Derivative liabilities are initially recognized at fair value at the date on which the derivative contract was entered into. Any attributable transaction costs are recognized in net loss as incurred. Subsequent to initial recognition, derivative liabilities are measured at fair value at each reporting date until settlement with the re-measurement gain or loss being recognized immediately in net loss and comprehensive loss. For more details on derivative liabilities consisting of the Altria Warrant, Pre-emptive Rights, and certain Top-up Rights, see Note 9 “Derivative Liabilities.”

Capital stock

Capital stock is presented at the fair value at the time of issuance of the shares issued. Costs related to the issuance of shares are reported in equity, net of tax, as a deduction from the issuance proceeds.

Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. The Company’s contracts with customers for the sale of dried flower, cannabis oil, cannabinoid-derived products and “hemp” (as defined in the U.S. Agricultural Improvement Act of 2018 “U.S. hemp”) derived products consist of a single performance obligation.

The Company has concluded that revenue from the sale of these products should be recognized at the point in time when control is transferred to the customer, depending on the specific contractual terms. The Company has determined that the most definitive demonstration that control has transferred to a customer is physical shipment or delivery, depending on the contractual shipping terms, except for consignment transactions. Consignment transactions are arrangements where the Company transfers product to a customer or third-party location but retains ownership and control of such product until it is used by the customer. Revenue for consignment arrangements is recognized upon the customer’s usage.

Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Net revenue before excise taxes from sale of goods, as presented in the consolidated statements of net loss and comprehensive loss, represents revenue from the sale of goods less expected price discounts, allowances for customer returns and other forms of variable consideration. If the consideration in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the goods to the customer. The variable consideration is estimated using either the expected value or most likely amount method, based on the Company’s historical information, at contract inception. The Company’s payment terms vary by customer and product type.

The Company treats shipping and handling activities as a fulfillment cost, classified as cost of sales. Accordingly, the Company accrues all fulfillment costs related to the shipping and handling of consumer goods at the time of shipment.

Research and development

The Company has a research and development center in Canada that performs scientific research on the interaction of cannabinoids as well as strain development, growing conditions and extraction technology. In 2023, fermentation and production related research was performed to further strategic initiatives around rare cannabinoids. In addition, the Company has a collaboration and license agreement with Ginkgo (the “Ginkgo Collaboration Agreement”) to research, produce, and commercialize cultured cannabinoids. Technological feasibility is considered to be established once productivity targets or commercialization are achieved, at which point the exclusive license is recognized at cost less impairment charges. As of the acquisition date of each exclusive license, cost less impairment charges is equal to the fair value. Refer to Note 7 “Goodwill and Intangible Assets, net” for more information on the Ginkgo Collaboration Arrangement. Research and development costs associated with these collective efforts are expensed as incurred as part of operating expenses in the Company’s consolidated statements of net loss and comprehensive loss.

Advertising costs

Advertising costsAdvertising costs include costs to sell the Company’s products and are expensed as incurred through sales and marketing expenses in the consolidated statements of net loss and comprehensive loss.

Share-based compensation

The Company has five share-based compensation plans under which awards have been made: the 2020 Omnibus Plan, the 2018 Stock Option Plan, the 2015 Stock Option Plan, the Employment Inducement Award Plan and the DSU Plan (each as defined below).

Share-based awards consists of equity-settled share-based awards such as stock options and restricted share units (“RSUs”) that are issued to eligible employees, non-executive directors, and non-employees. Cash-settled deferred share units (“DSUs”) that are issued to non-executive directors under the DSU Plan are recorded in accrued liabilities with the fair value adjustment recorded in other income.

Equity instruments granted are initially measured at fair value on the grant date. The fair value of stock options is determined using the Black-Scholes option pricing model. The fair value of RSUs and DSUs are determined using the market price of the Company’s common shares. Compensation expense related to options and RSUs is recognized on a straight-line basis in the consolidated statements of net loss and comprehensive loss over the vesting period for employees, and over the contractual term for non-employees. The fair value of the payout of cash-settled DSUs is determined at each reporting date based on the fair value of the Company’s common shares at the reporting date and is recorded within other liabilities. The related costs for all equity-settled share-based awards are reflected in additional paid-in capital until the awards are settled or exercised. Upon settlement or exercise, shares are issued and the amount previously reflected in additional paid-in capital is, along with any proceeds paid upon settlement or exercise, credited to a combination of share capital and additional paid-in capital. Forfeitures of share-based compensation awards are accounted for as reductions to share-based compensation and additional paid-in capital as they occur.

Impairment of long-lived assets

The Company reviews its long-lived assets, such as property, plant and equipment and definite-lived intangible assets, for impairment in accordance with Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment. In accordance with ASC Topic 360, long-lived assets to be held are reviewed for events or changes in circumstances that indicate that their carrying amount may not be recoverable. The Company periodically reviews for indicators and, if indicators are present, tests the carrying amount of long-lived assets, assessing their recoverable value based on estimated undiscounted cash flows over their remaining estimated useful lives. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. If the carrying amount of an asset (or asset group) exceeds its estimated undiscounted future cash flows, an impairment charge is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset group, based on discounted cash flows.

Assets held for sale and discontinued operations

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph ASC 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria, the major current assets, other assets, current liabilities, and other liabilities are reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), are reported as components of net loss separate from the net loss of continuing operations.

The Company periodically evaluates its long-lived assets that it plans to dispose of through sale for held-for-sale classification. To be classified as held-for-sale, management must have committed to a plan to sell, the asset (or asset group) must be available for immediate sale in its present condition, an active program to locate a buyer must have been initiated, the sale must be probable to close within one year, the asset (or asset group) must be marketed at a reasonable sales price, and it must be unlikely that significant changes to the plan will be made. Once an asset (or asset group) meets all of the above criteria, it is reclassified as assets held for sale on the consolidated balance sheet, and the asset(s) cease depreciation and are written down to their fair value, less costs to sell, if applicable.

The Company completed a review of its global supply chain and determined that it would wind down its Winnipeg, Manitoba facility (“Cronos Fermentation”) and list it for sale. This review involves significant complexities and judgments in making the accounting treatment determination. There are subjective and complex judgments in the determination of whether the Cronos Fermentation facility meets the criteria to be classified as held for sale, including: (1) whether the Cronos Fermentation facility is available for sale in its present condition subject only to terms that are usual and customary for sales of such businesses, (2) whether the sale of the

Cronos Fermentation facility is probable and that the transfer of assets will be a completed sale within one year from period end, and (3) whether the Cronos Fermentation facility is being actively marketed at a reasonable price. See Note 6 “Property, plant and equipment, net” for discussion regarding our evaluation of the Peace Naturals Campus and the Cronos Fermentation facility for held-for-sale classification as of December 31, 2023.

Impairment of goodwill and indefinite-lived intangible assets

Impairment of goodwill and indefinite-lived intangible assetsGoodwill and indefinite-lived intangible assets are not amortized. Goodwill and indefinite-lived intangible assets are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value of the reporting unit has been reduced to less than its carrying amount in accordance with the provisions of ASC Topic 350, Intangibles—Goodwill and Other. The Company performs an impairment test annually in the fourth quarter by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.

Income taxes

The Company uses the liability method of accounting for income taxes, under which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when such assets and liabilities are recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the year that includes the enactment date. The Company determines deferred tax assets including net operating losses and liabilities, based on temporary differences between the book and tax bases of assets and liabilities.

A valuation allowance is established to reduce some or all net deferred tax assets to amounts that are more likely than not to be realized. The Company considers all available evidence, both positive and negative, including past operating results, estimates of future taxable income, and the feasibility of tax planning strategies, in assessing the need for a valuation allowance.

A valuation allowance against some or all of the net deferred tax assets does not in any way impact the Company’s ability to use future tax deductions such as the Company’s net operating loss carryforwards; rather, the valuation allowance indicates, according to the provisions of ASC 740, Income Taxes, it is more likely than not that the deferred tax assets will not be realized. The valuation allowance that was established will be maintained until there is sufficient positive evidence to conclude that it is more likely than not that the net deferred tax assets will be realized. The Company’s income tax expense for future periods will be reduced to the extent of corresponding decreases in our valuation allowance. There is uncertainty regarding any future realization of the benefit by the Company of all or part of our net deferred tax assets.

Judgment is required to determine the recognition and measurement attributes prescribed in the accounting guidance for uncertainty in income taxes. The Company uses a two-step approach for evaluating uncertain tax positions. Step one, recognition, requires us to determine whether the weight of available evidence indicates that a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any. If a tax position is not considered “more likely than not” to be sustained, no benefits of the position are recognized. If we determine that a position is “more likely than not” to be sustained, then we proceed to step two, measurement, which is based on the largest amount of benefit which is more likely than not to be realized on effective settlement. This process involves estimating our actual current tax exposure, including assessing the risks associated with income tax audits, together with assessing temporary differences resulting from the different treatment of items for tax and financial reporting purposes. If actual results differ from our estimates, our net operating loss and credit carryforwards, to the extent not covered by a valuation allowance, could be materially impacted in the period which such determination is made.

The Company recognizes uncertain income tax positions at the largest amount that is more-likely-than-not to be sustained upon examination by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Recognition or measurement is reflected in the period in which the likelihood changes. Any interest and penalties related to unrecognized tax liabilities are presented within income tax expense in the consolidated statements of net loss and comprehensive loss. Accrued interest and penalties are included in accounts payable and other liabilities in the consolidated balance sheets.

Foreign currency

The Company’s functional currency is the Canadian dollar (“C$”) and its reporting currency is the U.S. dollar. Functional currencies for the entities in these consolidated financial statements are their respective local currencies, including C$, U.S. dollar and Israeli New Shekel (“ILS”). All assets and liabilities of operations with a functional currency other than the Canadian dollar are translated into Canadian dollars at the period-end currency exchange rates and subsequently translated into U.S. dollars at period-end currency exchange rates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss), net of tax. Revenues and expenses of operations, as well as all cash flows, with a functional currency other than the Canadian dollar are translated into Canadian dollars at the average exchange rates for the period and subsequently translated into U.S. dollars at the average exchange rates for the period. Transaction gains and losses resulting from changes in foreign currency exchange rates are recorded in either cost of sales, general and administrative expenses, or foreign currency transaction gain (loss) in the consolidated statements of net loss and comprehensive loss.

Segments

Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Historically, the Company has reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment. All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Annual Report. These reclassifications had no effect on our consolidated financial statements in any period presented.

Earnings (loss) per share

The Company presents basic and diluted earnings (loss) per share data for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all potentially dilutive common shares.

Fair value measurements

The carrying amount of the Company’s cash and cash equivalents, accounts receivable, other receivables, loans receivable, accounts payable and other liabilities approximate fair value, given their short-term nature. Cronos uses a fair value hierarchy, which gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities, noted as Level 1 measurements, and the lowest priority to unobservable inputs, noted as Level 3 measurements.

The following are the three levels of inputs used to measure fair value:

•Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities.

•Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

•Level 3 – valuation techniques using the inputs for the asset or liability that are not based on observable market data.

The Company’s policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer.

Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted

Adoption of new accounting pronouncements

On January 1, 2023, the Company adopted ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU 2022-02”). ASU 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. The adoption of ASU 2022-02 did not have a material impact on the Company’s consolidated financial statements.

(aa)New accounting pronouncements not yet adopted

In June 2022, the Financial Accounting Standards Board (“FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and we expect to adopt ASU 2022-03 prospectively. The Company does not expect the adoption of ASU 2022-03 to have a material impact on its consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information on the CODM and disclosures for entities with a single reportable segment. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-07 retrospectively. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the existing income tax disclosures to provide additional information to better assess how an entity’s operations, related tax risks and tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. ASU 2023-09 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-09 prospectively. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its consolidated financial statements.

Property, Plant and Equipment, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Aggregate depreciation expense		$ 3,913	$ 8,667	$ 11,668
Impairment loss on long-lived assets		$ 3,366	$ 3,493	126,405
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Impairment loss on long-lived assets	$ 1,507
Facility in Stayner, Ontario, Canada
Property, Plant and Equipment [Line Items]
Impairment loss on long-lived assets				$ 113,917

Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 1,132
2025	1,006
2026	247
2027	95
2028	95
Thereafter	412
Total lease payments	2,987
Less: imputed interest	(434)
Present value of lease liabilities	$ 2,553

Financial Instruments - Credit Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Maximum exposure to credit risk	$ 966,442	$ 987,836
Accounts receivable, net	$ 13,984	23,113
Accounts receivable, threshold period past due, writeoff	120 days
Net revenue, before excise taxes	$ 120,270	109,301	$ 79,612
Cash and cash equivalents	669,291	764,644
Short-term investments	192,237	113,077
Accounts payable, trade, current	8,887	8,599
United States
Concentration Risk [Line Items]
Current expected credit loss	$ 3	$ 219
One Major Customer \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	37.00%
Three Major Customers \| Rest of World
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 79,503		$ 41,603
Three Major Customers \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		55.00%
Three Major Customers \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk \| Rest of World
Concentration Risk [Line Items]
Concentration risk, percentage	66.00%	55.00%	56.00%
Net revenue, before excise taxes		$ 63,509

Investments - Schedule of Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 16, 2021	Dec. 15, 2021
Schedule of Equity Method Investments [Line Items]
Equity method investments, net	$ 19,488	$ 18,755
Share of income (loss) from equity method investments	1,583	3,114	$ (6,313)
Equity Method Investment, Summarized Financial Information [Abstract]
Current assets	933,306	960,156
Current liabilities	41,399	68,116
Income Statement [Abstract]
Revenue	87,241	86,749	64,561
Gross profit	11,909	15,436	(17,593)
Net income (loss)	(74,553)	(168,734)	(397,204)
Equity Method Investments
Equity Method Investment, Summarized Financial Information [Abstract]
Current assets	19,600	21,158	5,660
Non-current assets	99,227	104,227	125,777
Current liabilities	9,707	5,593	13,457
Non-current liabilities	64,814	73,779	81,594
Income Statement [Abstract]
Revenue	40,604	39,110	8,186
Gross profit	21,565	24,379	(5,059)
Net income (loss)	$ 3,051	$ 6,569	(12,603)
Vitura
Schedule of Equity Method Investments [Line Items]
Ownership interest				10.00%	31.00%
Share of income (loss) from equity method investments			(48)
Ownership interest	9.60%	9.90%
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%	50.00%
Equity method investments, net	$ 19,488	$ 18,755
Share of income (loss) from equity method investments	$ 1,583	$ 3,114	(2,518)
Natuera
Schedule of Equity Method Investments [Line Items]
Share of income (loss) from equity method investments			$ (3,747)

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Vaughan, Ontario, Canada
Auditor Firm ID	85

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Cost	$ 43,933	$ 42,274
Accumulated amortization	(9,659)	(6,062)
Accumulated impairment charges	(14,696)	(11,008)
Net	19,578	25,204
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Cost	108,075	106,416
Accumulated amortization	(9,659)	(6,062)
Accumulated impairment charges	(77,338)	(73,650)	$ (74,308)	$ (6,053)
Total intangible assets	21,078	26,704
Lord Jones brand
Indefinite-lived Intangible Assets [Line Items]
Cost	64,000	64,000
Accumulated impairment charges	(62,500)	(62,500)	(62,500)	(5,000)
Indefinite-Lived Intangible Assets (Excluding Goodwill), Total	1,500	1,500
Trademarks
Indefinite-lived Intangible Assets [Line Items]
Cost	142	142
Accumulated impairment charges	(142)	(142)	(142)	0
Indefinite-Lived Intangible Assets (Excluding Goodwill), Total	0	0
Software
Finite-Lived Intangible Assets [Line Items]
Cost	6,860	6,037
Accumulated amortization	(3,508)	(2,388)
Accumulated impairment charges	(78)	(76)	(4)	0
Net	3,274	3,573
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(3,508)	(2,388)
Health Canada licenses
Finite-Lived Intangible Assets [Line Items]
Cost	8,463	8,269
Accumulated amortization	(1,813)	(1,771)
Accumulated impairment charges	(6,650)	(6,498)	(6,910)	(1,053)
Net	0	0
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(1,813)	(1,771)
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Cost	28,326	27,676
Accumulated amortization	(4,276)	(1,854)
Accumulated impairment charges	(7,968)	(4,434)	$ (4,752)	$ 0
Net	16,082	21,388
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(4,276)	(1,854)
Israeli codes
Finite-Lived Intangible Assets [Line Items]
Cost	284	292
Accumulated amortization	(62)	(49)
Net	222	243
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	$ (62)	$ (49)

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Consolidated Entities (Details)	12 Months Ended
	Dec. 31, 2023
Cronos Israel G.S. Cultivations Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	70.00%
Cronos Israel G.S. Manufacturing Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%
Cronos Israel G.S. Store Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%
Cronos Israel G.S. Pharmacy Ltd.
Subsidiary or Equity Method Investee [Line Items]
Ownership interest	90.00%

Share-based Compensation - Summary of Deferred Share Units Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Weighted average grant date fair value
Grants	$ 8,756	$ 15,008	$ 9,844
Deferred Share Units (DSUs)
Weighted average grant date fair value
Balance at beginning of period	674	408
Grants	450	443
Gain on revaluation	(32)	(177)
Balance at end of period	$ 1,092	$ 674	$ 408
Number of DSUs
Balance at beginning of period (in shares)	265,732	104,442
Granting and vesting of DSUs (in shares)	255,947	161,290
Balance at end of period (in shares)	521,679	265,732	104,442

Investments - Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Investments [Roll Forward]
Other Investments, beginning balance				$ 118,392	$ 70,993	$ 118,392
Unrealized gain (loss)					(12,096)	14,739
Impairment charges					(23,350)	(61,392)	$ 0
Foreign exchange effect					(296)	(746)
Other Investments, ending balance	$ 35,251	$ 70,993			35,251	70,993	118,392
Pharmacann
Other Investments [Roll Forward]
Other Investments, beginning balance				110,392	49,000	110,392
Unrealized gain (loss)					0	0
Impairment charges	(23,350)	(21,182)	$ (28,972)	(11,238)	(23,350)	(61,392)
Foreign exchange effect					0	0
Other Investments, ending balance	25,650	49,000			25,650	49,000	110,392
Vitura
Other Investments [Roll Forward]
Other Investments, beginning balance				$ 8,000	21,993	8,000
Unrealized gain (loss)					(12,096)	14,739
Impairment charges					0	0
Foreign exchange effect					(296)	(746)
Other Investments, ending balance	$ 9,601	$ 21,993			$ 9,601	$ 21,993	$ 8,000

Loss per Share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Earnings (Loss) Per Share

Basic and diluted earnings (loss) per share from continued and discontinued operations are calculated as follows:


	Year ended December 31,
	2023		2022		2021
Basic loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$	(69,849)	$	(155,178)	$	(126,982)
Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share(i)	380,964,739		376,961,797		370,390,965
Basic loss from continuing operations per share	$	(0.18)	$	(0.41)	$	(0.34)
Diluted loss per share from continuing operations	$	(0.18)	$	(0.41)	$	(0.34)

Loss from discontinued operations attributable to the shareholders of Cronos Group	$	(4,114)	$	(13,556)	$	(269,125)
Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share(i)	380,964,739		376,961,797		370,390,965
Basic loss from discontinued operations per share	$	(0.01)	$	(0.04)	$	(0.73)
Diluted loss from discontinued operations per share	$	(0.01)	$	(0.04)	$	(0.73)

(i)In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Discontinued Operations - Reconciliation of Assets and Liabilities of Discontinued Operations (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 0	$ 2,300
Accounts receivable, net	0	253
Other receivables	0	775
Prepaids and other current assets	0	464
Inventory, net	0	934
Current assets of discontinued operations	0	4,726
Non-current assets
Property, plant and equipment, net	0	254
Right-of-use assets	0	430
Intangible assets, net	0	1,594
Non-current assets of discontinued operations	0	2,278
Current liabilities
Accounts payable	0	166
Accrued liabilities	0	807
Current portion of lease obligation	0	415
Current liabilities of discontinued operations	$ 0	$ 1,388

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (74,553)	$ (168,734)	$ (397,204)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	8,769	15,115	10,151
Depreciation and amortization	8,110	13,122	15,402
Impairment loss on goodwill and indefinite-lived intangible assets	0	0	236,056
Impairment loss on long-lived assets	3,571	3,493	127,619
Impairment loss on other investments	23,350	61,392	0
Income from investments	10,513	(17,853)	(1,974)
Loss (gain) on revaluation of derivative liabilities	85	(14,060)	(151,360)
Changes in expected credit losses on long-term financial assets	(1,528)	(662)	12,202
Foreign currency transaction loss	7,324	2,286	0
Other non-cash operating activities, net	(2,008)	1,294	335
Changes in operating assets and liabilities:
Accounts receivable, net	9,206	(2,711)	(13,163)
Interest receivable	(14,344)	(6,985)	(2,497)
Other receivables	(1,449)	1,148	3,497
Prepaids and other current assets	1,437	996	3,102
Inventory, net	7,399	(7,217)	11,565
Accounts payable	(773)	(863)	(1,597)
Income taxes payable	(33,104)	34,212	(776)
Accrued liabilities	5,160	(2,921)	(4,974)
Net cash used in operating activities	(42,835)	(88,948)	(153,616)
Investing activities
Proceeds from short-term investments	532,838	268,870	215,303
Purchase of short-term investments	(608,247)	(271,378)	(119,610)
Dividends received from equity method investee	1,297	0	0
Purchase of investments	0	0	(110,392)
Dividend proceeds	345	384	0
Repayments (advances) on loan receivables	16,831	5,246	(4,967)
Purchase of property, plant and equipment, net of disposals	(2,505)	(3,451)	(11,144)
Purchase of intangible assets, net of disposals	(918)	(1,581)	(1,118)
Other investing activities	860	68	3,030
Net cash used in investing activities	(59,499)	(1,842)	(28,898)
Financing activities
Withholding taxes paid on equity awards	(1,030)	(2,829)	(13,458)
Other financing activities, net	0	(68)	16
Net cash used in financing activities	(1,030)	(2,897)	(13,442)
Effect of foreign currency translation on cash and cash equivalents	8,011	(28,642)	4,906
Net change in cash and cash equivalents	(95,353)	(122,329)	(191,050)
Cash and cash equivalents, beginning of period	764,644	886,973	1,078,023
Cash and cash equivalents, end of period	669,291	764,644	886,973
Supplementary cash flow information(i):
Interest Paid, Excluding Capitalized Interest, Operating Activities	0	0	0
Interest received	36,501	15,548	8,988
Taxes paid	$ 33,013	$ 177	$ 892

Discontinued Operations - Major Components Comprising Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
Net loss from discontinued operations	$ (4,114)	$ (13,556)	$ (269,125)
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	1,029	5,155	9,874
Cost of sales	2,164	8,622	9,850
Inventory write-down	839	0	0
Gross profit	(1,974)	(3,467)	24
Operating expenses
Sales and marketing	578	4,236	24,020
Research and development	32	250	1,490
General and administrative	668	3,504	6,133
Restructuring costs	523	1,788	0
Share-based compensation	13	107	307
Depreciation and amortization	13	58	71
Impairment loss on goodwill and indefinite-lived intangible assets	0	0	236,019
Impairment loss on long-lived assets	205	0	1,214
Total operating expenses	2,032	9,943	269,254
Interest income	10	23	4
Other, net	(118)	(169)	101
Total other loss	(108)	(146)	105
Loss before income taxes	(4,114)	(13,556)	(269,125)
Income tax expense (benefit)	0	0	0
Net loss from discontinued operations	(4,114)	$ (13,556)	(269,125)
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| United States
Operating expenses
Goodwill impairment			178,414
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| United States \| Lord Jones brand
Operating expenses
Intangible asset impairment			$ 57,500
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| Facility in Los Angeles, California
Operating expenses
Impairment loss on long-lived assets	$ 205

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Summary of Discontinued Operations

The following table presents the major components comprising loss from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021:


	Year ended December 31, 2023		Year ended December 31, 2022		Year ended December 31, 2021(iv)
Net revenue	$	1,029	$	5,155	$	9,874
Cost of sales	2,164		8,622		9,850
Inventory write-down(i)	839		—		—
Gross profit	(1,974)		(3,467)		24
Operating expenses
Sales and marketing	578		4,236		24,020
Research and development	32		250		1,490
General and administrative	668		3,504		6,133
Restructuring costs	523		1,788		—
Share-based compensation	13		107		307
Depreciation and amortization	13		58		71
Impairment loss on goodwill and indefinite-lived intangible assets	—		—		236,019
Impairment loss on long-lived assets(ii)	205		—		1,214
Total operating expenses	2,032		9,943		269,254
Interest income	10		23		4
Other, net(iii)	(118)		(169)		101
Total other loss	(108)		(146)		105
Loss before income taxes	(4,114)		(13,556)		(269,125)
Income tax expense (benefit)	—		—		—
Net loss from discontinued operations	(4,114)		(13,556)		(269,125)

(i)For the year ended December 31, 2023, Inventory write-down relates to the disposal of obsolete inventory as a result of the exit of the U.S. operations.

(ii)During the year ended December 31, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California. For the year ended December 31, 2021, the Company concluded that the carrying amount of the U.S. reporting unit exceeded its fair value, which resulted in the recognition of an impairment charge of $178,414 on goodwill and concluded the carrying amount of the Lord Jones® brand exceeded its fair value, which resulted in impairment charges of $57,500 on its Lord Jones® brand intangible asset.

(iii)For the years ended December 31, 2023 and December 31, 2022, Other, net related to loss on disposal of assets that were part of the U.S. operations. For the year ended December 31, 2021, Other, net includes a gain on disposal of assets related to Original B.C. Ltd. (“OGBC”) as well as a loss from disposal of assets that were part of the U.S. operations.

(iv)2021 loss from discontinued operations includes amounts related to the discontinuance of OGBC.

The following tables present the Company’s discontinued operations revenue by major product category:



	2023		2022		2021
Cannabis extracts	1,029		5,155		9,874
Net revenue	$	1,029	$	5,155	$	9,874

The following table presents a reconciliation of assets and liabilities of the discontinued operations presented in the consolidated balance sheets:


	As of December 31, 2023		As of December 31, 2022
Assets
Current assets
Cash and cash equivalents	$	—	$	2,300

Accounts receivable, net	—		253
Other receivables	—		775

Prepaids and other current assets	—		464
Inventory, net	—		934
Current assets of discontinued operations	—		4,726

Non-current assets



Property, plant and equipment, net	—		254
Right-of-use assets	—		430

Intangible assets, net	—		1,594

Non-current assets of discontinued operations	—		2,278

Liabilities
Current liabilities
Accounts payable	—		166

Accrued liabilities	—		807
Current portion of lease obligation	—		415


Current liabilities of discontinued operations	$	—	$	1,388

The following table presents information related to leases associated with the Company’s U.S. discontinued operations. As of December 31, 2023, the Company has no right-of-use assets or lease obligations associated with its U.S. discontinued operations. For the years ended December 31, 2023, 2022 and 2021, the aggregate depreciation expense on right-of-use assets associated with the Company’s U.S. discontinued operations was $198, $865 and $548, respectively, and was included in loss from discontinued operations on the consolidated statements of net loss and comprehensive loss.


	As of December 31,
	2023			2022			2021
Lease cost
Operating lease cost	$	213		$	1,102		$	837
Short-term lease cost	—			—			—
Total lease cost	$	213		$	1,102		$	837

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	525		$	1,050		$	752
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			443			3,277

Weighted-average remaining lease term (years) – operating leases	0.0			1.0			3.8
Weighted-average discount rate – operating leases	—		%	5.62		%	7.65		%

Schedule of Plan Information and Restructuring-Related Costs

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of January 1, 2023		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of January 1, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2023 and 2022:


	As of January 1, 2023		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150


	As of January 1, 2022		Expenses		Payments/Write-offs		As of December 31, 2022
Employee Termination Benefits	$	—	$	1,883	$	(1,480)	$	403

Other Restructuring Costs	—		1,662		(1,641)		21
Total	$	—	$	3,545	$	(3,121)	$	424

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-3

+ Details

Background, Basis of Presentation, and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Background, Basis of Presentation, and Summary of Significant Accounting Policies

(a)Background

Cronos Group Inc. (“Cronos” or the “Company”) is incorporated in the province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.”

Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®.

(b)Basis of presentation

(c)Basis of consolidation

The accompanying consolidated financial statements include the accounts of the Company, and all entities in which the Company has a controlling voting interest or is the primary beneficiary of a variable interest as of and for the reporting periods. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. If an entity is not deemed to be a VIE, the Company consolidates the entity if the Company has a controlling voting interest. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. Investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not have control, are accounted for under the equity method of accounting. The Company consolidates the financial results of the following entities, which the Company controls but does not wholly own:

Subsidiaries

Jurisdiction of incorporation

Incorporation date

Ownership interest (ii)

Cronos Israel G.S. Cultivation Ltd.(i)

Israel

February 4, 2018

70%

Cronos Israel G.S. Manufacturing Ltd.(i)

Israel

September 4, 2018

90%

Cronos Israel G.S. Store Ltd.(i)

Israel

June 28, 2018

90%

Cronos Israel G.S. Pharmacy Ltd.(i)

Israel

February 15, 2018

90%

(i)These Israeli entities are collectively referred to as “Cronos Israel.”

(ii)“Ownership interest” is defined as the proportionate share of net income to which the Company is entitled; equity interest may differ from ownership interest as described herein.

(d)Use of estimates

inventory write-downs, share-bared payments, valuation allowance on deferred income tax assets and uncertain tax liabilities. Actual results could differ from those estimates.

(e)Cash and cash equivalents and short-term investments

(f)Inventory

(g)Investments

Variable interest entities

Equity method investments

Other investments

(h)Property, plant and equipment

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

5 to 7 years

Furniture and fixtures

5 years

(i)Definite-lived intangible assets

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities

(j)Accrued liabilities

Accrued liabilities consist of the following:


	As of December 31,
	2023		2022
Accrued payroll and related expenses	$	8,970	$	11,492
Accrued professional fees	2,525		2,414
Accrued taxes	11,695		4,132
Other accrued expenses	4,546		4,230
Total accrued liabilities	$	27,736	$	22,268

(k)Leases

(l)Derivative liabilities

(m)Capital stock

(n)Revenue recognition

The following table presents the Company's revenue by major product category for continuing operations:


	Year ended December 31,
	2023		2022		2021
Cannabis flower	$	62,070	$	63,593	$	55,194
Cannabis extracts	24,569		22,522		8,807
Other	602		634		560
Net revenue	$	87,241	$	86,749	$	64,561

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2023		2022		2021
Canada	$	64,702	$	56,233	$	50,294
Israel	21,134		30,516		13,376

Other countries	1,405		—		891
Net revenue	$	87,241	$	86,749	$	64,561

(o)Research and development

(p)Advertising costs

Advertising costs include costs to sell the Company’s products and are expensed as incurred through sales and marketing expenses in the consolidated statements of net loss and comprehensive loss. Advertising costs were $1,382, $889 and $2,229 for the years ended December 31, 2023, 2022, and 2021, respectively.

(q)Share-based compensation

(r)Impairment of long-lived assets

(s)Assets held for sale and discontinued operations

(t)Impairment of goodwill and indefinite-lived intangible assets

Goodwill and indefinite-lived intangible assets are not amortized. Goodwill and indefinite-lived intangible assets are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value of the reporting unit has been reduced to less than its carrying amount in accordance with the provisions of ASC Topic 350, Intangibles—Goodwill and Other. The Company performs an impairment test annually in the fourth quarter by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.

(u)Income taxes

(v)Foreign currency

(w)Segments

(x)Earnings (loss) per share

(y)Fair value measurements

The following are the three levels of inputs used to measure fair value:

•Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities.

•Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

•Level 3 – valuation techniques using the inputs for the asset or liability that are not based on observable market data.

The Company’s policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer.

(z)Adoption of new accounting pronouncements

(aa)New accounting pronouncements not yet adopted

Consolidated Balance Sheet (Parenthetical) - shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	381,298,853	380,575,403
Common stock, shares outstanding (in shares)	381,298,853	380,575,403

Share-based Compensation - Summary of Restricted Share Units Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Weighted average grant date fair value
Exercised (in dollars per share)		$ 2.79
Number of RSUs
Exercised (in shares)		(2,735,985)
Restricted Stock Units (RSUs)
Weighted average grant date fair value
Balance at beginning of period (in dollars per share)	$ 4.63	$ 9.22
Granted (in dollars per share)	2.64	4.27
Exercised (in dollars per share)	5.00	7.40
Cancellation and forfeitures (in dollars per share)	3.60	5.08
Balance at end of period (in dollars per share)	$ 3.77	$ 4.63
Number of RSUs
Balance at beginning of period (in shares)	5,725,470	1,225,870
Granted (in shares)	3,292,586	6,140,492
Exercised (in shares)	(1,041,097)	(1,151,292)
Cancellation and forfeitures (in shares)	(595,418)	(489,600)
Balance at end of period (in shares)	7,381,541	5,725,470
Vesting period	3 years
Restricted Stock Units (RSUs) \| Minimum
Number of RSUs
Cliff period	3 years
Restricted Stock Units (RSUs) \| Maximum
Number of RSUs
Cliff period	5 years

Investments (Tables)

12 Months Ended

Dec. 31, 2023

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Investments

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2023		2022

Cronos GrowCo	50%	$	19,488	$	18,755

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2023		2022		2021
Vitura(i)	N/A		N/A		$	(48)
Cronos GrowCo	1,583		3,114		(2,518)
Natuera(ii)	N/A		N/A		(3,747)
	$	1,583	$	3,114	$	(6,313)

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2023		2022		2021
Current assets	$	19,600	$	21,158	$	5,660
Non-current assets	99,227		104,227		125,777
Current liabilities	9,707		5,593		13,457
Non-current liabilities	64,814		73,779		81,594


	Year ended December 31,
	2023		2022		2021
Revenue	$	40,604	$	39,110	$	8,186
Gross profit	21,565		24,379		(5,059)
Net income (loss)	3,051		6,569		(12,603)

The following table summarizes the Company’s other investments activity:


	As of January 1, 2023		Unrealized loss		Impairment charges		Foreign exchange effect		As of December 31, 2023
PharmaCann	$	49,000	$	—	$	(23,350)	$	—	$	25,650
Vitura	21,993		(12,096)		—		(296)		9,601
	$	70,993	$	(12,096)	$	(23,350)	$	(296)	$	35,251


	As of January 1, 2022		Unrealized gain		Impairment charges		Foreign exchange effect		As of December 31, 2022
PharmaCann	$	110,392	$	—	$	(61,392)	$	—	$	49,000
Vitura	8,000		14,739		—		(746)		21,993
	$	118,392	$	14,739	$	(61,392)	$	(746)	$	70,993

Schedule of Variable Interest Entities

A reconciliation of the carrying amount of the investments in equity method investments, net is as follows:


	Ownership interest	As of December 31,
		2023		2022

Cronos GrowCo	50%	$	19,488	$	18,755

The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:


	Year ended December 31,
	2023		2022		2021
Vitura(i)	N/A		N/A		$	(48)
Cronos GrowCo	1,583		3,114		(2,518)
Natuera(ii)	N/A		N/A		(3,747)
	$	1,583	$	3,114	$	(6,313)

The following is a summary of financial information for the Company’s equity method investments:


	As of December 31,
	2023		2022		2021
Current assets	$	19,600	$	21,158	$	5,660
Non-current assets	99,227		104,227		125,777
Current liabilities	9,707		5,593		13,457
Non-current liabilities	64,814		73,779		81,594


	Year ended December 31,
	2023		2022		2021
Revenue	$	40,604	$	39,110	$	8,186
Gross profit	21,565		24,379		(5,059)
Net income (loss)	3,051		6,569		(12,603)

The following is a summary of the maximum exposure to loss from the Company’s investments in equity method investments:


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss

Cronos GrowCo	50%	$	44,306	$	19,488

Balance as of December 31, 2023		$	44,306	$	19,488


	Ownership interest	Other Net Assets (Liabilities)		Maximum Exposure to Loss
Cronos GrowCo	50%	$	46,013	$	18,755


Balance as of December 31, 2022		$	46,013	$	18,755

The Company’s maximum exposure to loss is equal to the carrying amount of the investment.

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Discontinued Operations

12 Months Ended

Dec. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on the Company’s operations and financial results, and as such,

qualifies for reporting as discontinued operations in our consolidated statements of net loss and comprehensive loss. Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations.

The following table presents the major components comprising loss from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021:


	Year ended December 31, 2023		Year ended December 31, 2022		Year ended December 31, 2021(iv)
Net revenue	$	1,029	$	5,155	$	9,874
Cost of sales	2,164		8,622		9,850
Inventory write-down(i)	839		—		—
Gross profit	(1,974)		(3,467)		24
Operating expenses
Sales and marketing	578		4,236		24,020
Research and development	32		250		1,490
General and administrative	668		3,504		6,133
Restructuring costs	523		1,788		—
Share-based compensation	13		107		307
Depreciation and amortization	13		58		71
Impairment loss on goodwill and indefinite-lived intangible assets	—		—		236,019
Impairment loss on long-lived assets(ii)	205		—		1,214
Total operating expenses	2,032		9,943		269,254
Interest income	10		23		4
Other, net(iii)	(118)		(169)		101
Total other loss	(108)		(146)		105
Loss before income taxes	(4,114)		(13,556)		(269,125)
Income tax expense (benefit)	—		—		—
Net loss from discontinued operations	(4,114)		(13,556)		(269,125)

(i)For the year ended December 31, 2023, Inventory write-down relates to the disposal of obsolete inventory as a result of the exit of the U.S. operations.

(iv)2021 loss from discontinued operations includes amounts related to the discontinuance of OGBC.

The following tables present the Company’s discontinued operations revenue by major product category:



	2023		2022		2021
Cannabis extracts	1,029		5,155		9,874
Net revenue	$	1,029	$	5,155	$	9,874

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of January 1, 2023		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of January 1, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

The Company’s discontinued operations incurred no restructuring costs for the year ended December 31, 2021.

The following table presents a reconciliation of assets and liabilities of the discontinued operations presented in the consolidated balance sheets:


	As of December 31, 2023		As of December 31, 2022
Assets
Current assets
Cash and cash equivalents	$	—	$	2,300

Accounts receivable, net	—		253
Other receivables	—		775

Prepaids and other current assets	—		464
Inventory, net	—		934
Current assets of discontinued operations	—		4,726

Non-current assets



Property, plant and equipment, net	—		254
Right-of-use assets	—		430

Intangible assets, net	—		1,594

Non-current assets of discontinued operations	—		2,278

Liabilities
Current liabilities
Accounts payable	—		166

Accrued liabilities	—		807
Current portion of lease obligation	—		415


Current liabilities of discontinued operations	$	—	$	1,388

For the years ended December 31, 2023, 2022 and 2021, purchases of property plant and equipment related to discontinued operations were $67, $183 and $971, respectively.


	As of December 31,
	2023			2022			2021
Lease cost
Operating lease cost	$	213		$	1,102		$	837
Short-term lease cost	—			—			—
Total lease cost	$	213		$	1,102		$	837

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	525		$	1,050		$	752
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			443			3,277

Weighted-average remaining lease term (years) – operating leases	0.0			1.0			3.8
Weighted-average discount rate – operating leases	—		%	5.62		%	7.65		%

Goodwill and Intangible Assets, net - Narrative (Details) $ / shares in Units, $ / shares in Units, $ in Thousands					1 Months Ended						12 Months Ended
	Nov. 12, 2021 USD ($) shares	Nov. 12, 2021 CAD ($) shares	Aug. 21, 2021 USD ($) shares	Aug. 21, 2021 CAD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 CAD ($) shares	Nov. 30, 2022 USD ($) shares	Nov. 30, 2022 CAD ($) $ / shares shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 CAD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 $ / shares	Nov. 12, 2021 $ / shares	Aug. 21, 2021 $ / shares	Jun. 14, 2021 $ / shares
Finite-Lived Intangible Assets [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares																	$ 0.0001
Purchase of intangible assets											$ 918,000	$ 1,581,000	$ 1,118,000
Finite-lived intangible assets, net					$ 25,204,000						19,578,000	25,204,000
Amortization of intangible assets											3,514,000	2,751,000	1,800,000
CBGA Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares																$ 7.90
Consideration given			$ 9,042,000	$ 11,593
Fair value			$ 7,300,000
Useful life (in years)			10 years
Period decrease													1,784,000
CBGA Licensing Agreement \| Common Shares
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) \| shares			1,467,490	1,467,490
CBGVA Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares															$ 7.12
Consideration given	$ 8,150,000	$ 10,449
Fair value	$ 5,300,000
Useful life (in years)	10 years
Period decrease													3,008,000
CBGVA Licensing Agreement \| Common Shares
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) \| shares	1,467,490	1,467,490
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares										$ 3.47
Consideration given									$ 6,522,000	$ 8,412
Useful life (in years)										10 years
Purchase of intangible assets									$ 600,000
Impairment charges											3,366,000	0	$ 4,792,000
Finite-lived intangible assets, net					21,388,000						16,082,000	$ 21,388,000
Ginkgo exclusive licenses \| Common Shares
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) \| shares									2,201,236	2,201,236
CBCA Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Consideration given							$ 1,473,000	$ 2,010
Useful life (in years)								10 years
CBCA Licensing Agreement \| Common Shares
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) \| shares							489,163	489,163
Sale of stock, price per share (in dollars per share) \| $ / shares								$ 4.11
CBCVA Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Consideration given					$ 3,724,000	$ 5,048
Impairment charges											3,366,000
Finite-lived intangible assets, net											$ 0
CBCVA Licensing Agreement \| Common Shares
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) \| shares					1,467,490	1,467,490
Sale of stock, price per share (in dollars per share) \| $ / shares														$ 3.44

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

The Company has entered into leases primarily for the land-use rights, office premises and equipment used in the production of cannabis and other related products. The Company’s leases have terms that range from three years to six years, excluding land use rights, which generally extend to 15 years. These leases often include options to extend the term of the lease for up to 10 years. When it is reasonably certain that the option will be exercised, the impact of the option is included in the lease term for purposes of determining total future lease payments.

Operating leases greater than one year are included in right-of-use assets and operating lease liabilities. Finance leases are included in property, plant and equipment on the Company’s consolidated balance sheet. The Company’s finance leases were not material for any of the periods presented.


	As of December 31,
	2023			2022			2021
Lease cost
Operating lease cost	$	685		$	1,107		$	1,693
Short-term lease cost	—			—			10
Total lease cost	$	685		$	1,107		$	1,703

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	1,124		$	1,441		$	1,706
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			—			—

Weighted-average remaining lease term (years) – operating leases	3.6			4.3			4.7
Weighted-average discount rate – operating leases	7.62		%	7.39		%	7.62		%

For the years ended December 31, 2023, 2022 and 2021, the aggregate depreciation expense on right-of-use assets was $455, $839 and $1,386, respectively, and was included in general and administrative expenses on the consolidated statements of net loss and comprehensive loss.

During the year ended December 31, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease.

The following is a summary of the Company’s future minimum lease payments under operating leases for its premises due in future fiscal years:


	As of December 31, 2023
2024	$	1,132
2025	1,006
2026	247
2027	95
2028	95
Thereafter	412
Total lease payments	2,987
Less: imputed interest	(434)
Present value of lease liabilities	$	2,553

In addition to the minimum lease payments, the Company is required to pay realty taxes and other occupancy costs in accordance with the terms of the lease agreements.

Financial Instruments - Foreign Currency Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Foreign exchange gain (loss) on translation	$ 21,539	$ (50,616)	$ 8,192
Impact of ten percent change in exchange rate	$ 97,678	$ 77,414

Loans Receivable, net (Tables)

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

Schedule of Loan Receivable

Loans receivable, net consists of the following:


	As of December 31,
	2023		2022


GrowCo Credit Facility	$	5,034	$	4,427
Add: Accrued interest	507		4,463
Total current portion of loans receivable	5,541		8,890
GrowCo Credit Facility	53,638		56,898
Mucci Promissory Note	13,379		13,438
Cannasoul Collaboration Loan	1,771		1,837
Add: Long-term portion of accrued interest	248		172
Total long-term portion of loans receivable	69,036		72,345
Total loans receivable	$	74,577	$	81,235

Financing Receivable, Allowance for Credit Loss

Expected credit loss allowances on the Company’s long-term financial assets were comprised of the following items:


	As of January 1, 2023		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2023
GrowCo Credit Facility	$	12,455	$	(1,542)	$	263	$	11,176

Mucci Promissory Note	89		(2)		2		89
Cannasoul Collaboration Loan	522		16		(14)		524
	$	13,066	$	(1,528)	$	251	$	11,789


	As of January 1, 2022		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2022
GrowCo Credit Facility	$	14,089	$	(827)	$	(807)	$	12,455

Mucci Promissory Note	90		4		(5)		89
Cannasoul Collaboration Loan	415		161		(54)		522
	$	14,594	$	(662)	$	(866)	$	13,066

(i)During the years ended December 31, 2023 and 2022, $(1,528) and $(662), respectively, were recorded to general and administrative expenses on the consolidated statements of net loss and comprehensive loss as a result of adjustments to our expected credit losses.

Share-based Compensation - Stock Options Narrative (Details) - Stock options - $ / shares	Mar. 29, 2020	Dec. 31, 2023	Dec. 31, 2022	Jun. 25, 2020	Jun. 28, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)		$ 2.96	$ 4.2
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Future awards to be granted (in shares)					0
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Future awards to be granted (in shares)				0
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)		$ 2.07	$ 2.94

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) before Income Taxes

For financial reporting purposes, loss from continuing operations before income taxes includes the following components:


	Year ended December 31,
	2023		2022		2021
Loss before income taxes	$	(73,669)	$	(121,003)	$	(128,510)

Schedule of Expense for Income Taxes

Income tax expense (benefit) consists of the following components:


	Year Ended December 31,
	2023		2022		2021
Current	$	(3,375)	$	34,416	$	(471)
Deferred	145		(241)		40
Total	$	(3,230)	$	34,175	$	(431)

Schedule of Effective Income Tax Rate Reconciliation

Reconciliation of the expected income tax to the effective tax rate in continuing operations is as follows:


	Year ended December 31,
	2023			2022				2021
Loss before income taxes	$	(73,669)		$	(121,003)		$	$	(128,510)
Effective income tax rate	26.5		%	26.5		%		26.5		%
Expected income tax benefit	$	(19,522)		$	(32,066)			$	(34,055)

Non-taxable income (loss)	1,077			(2,140)				39
Non-deductible share-based compensation	525			1,198				1,667
Non-deductible expenses	459			836				53
Non-deductible transaction costs	351			1,625				2,917
Effect of provincial tax rate difference	(9)			(15)				(1)
Effect of tax rates outside of Canada	816			1,848				(1,869)
Effect of change in tax rates	4,601			11,041				—
Fair value gain (loss) on financial liabilities	23			(3,726)				(40,111)
Changes in valuation allowance	7,930			(10,466)				70,453
Capital gain on financial liabilities	106			66,193				—
Other	413			(153)				476
Income tax expense (benefit), net	$	(3,230)		$	34,175			$	(431)

Schedule of Deferred Tax Assets and Liabilities

The following table summarizes the significant components of the Company’s deferred tax assets and liabilities:


	As of December 31,
	2023		2022
Deferred assets:
Tax loss carryforwards	$	111,516	$	98,074
Interest expense carryforwards	2,688		2,533
Deferred financing costs	—		1,311
Share issuance cost	—		196
Finance lease obligation	519		690
Plant and equipment	36,697		37,662
Investment	19,745		13,359
Intangible asset	37,203		53,365
Inventory	556		1,287
Reserve	2,430		2,972
Unrealized foreign exchange	275		—
R&D investment tax credits	567		293
Other	4,271		3,099
Total deferred tax assets	216,467		214,841
Less valuation allowance	(216,241)		(214,199)
Net deferred tax assets	226		642
Deferred tax liabilities:





Right-of-use assets	(181)		(365)
Unrealized foreign exchange	—		(84)
Total deferred tax liabilities	(181)		(449)
Net deferred tax asset (liability)(i)	$	45	$	193

(i)Net deferred tax asset (liability) is reported as Other assets within our consolidated balance sheet.

Summary of Income Tax Examinations


Jurisdiction						Open Years
Canada						2019 – 2023
United States						2020 – 2023
Israel						2020 – 2023

Share-based Compensation - Schedule of Stock Options Outstanding (Details) - shares	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,103,201	5,350,600	8,939,330
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	702,264	2,788,947	2,900,000
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	1,400,937	1,422,069	1,550,074
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	0	1,139,584	4,489,256

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Share-based Compensation

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Share-based Compensation

(a)Share-based award plans

The Company has granted stock options, RSUs and DSUs to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan.

The following table summarizes the total share-based compensation associated with the Company’s stock options and RSUs:


	Year ended December 31,
	2023		2022		2021
Stock options	$	1,175	$	6,778	$	7,604
RSUs	7,581		7,633		2,240
Liability-classified awards(i)	—		597		—
Total share-based compensation	$	8,756	$	15,008	$	9,844

(i)Represents share-based compensation awards conditionally approved for grant to one of the Company’s former executives for a fixed monetary value, but a variable number of shares. These awards were liability-classified until the number of shares was determined.

(b)Stock options

The Company adopted the 2015 Stock Option Plan, which was approved by shareholders of the Company at the annual general meeting of shareholders held on June 28, 2017. The 2015 Stock Option Plan allowed the Board to award options to purchase shares to directors, officers, key employees and service providers of the Company. As of June 28, 2018, no further awards will be granted under the 2015 Stock Option Plan; as of December 31, 2023, no options issued under the 2015 Stock Option Plan remain outstanding.

On June 28, 2018, the shareholders of the Company approved the 2018 Stock Option Plan, which replaced the 2015 Stock Option Plan. The 2018 Stock Option Plan terminated the Company’s ability to grant equity under the 2015 Stock Option Plan. As of June 25, 2020, the date on which the 2020 Omnibus Plan was approved by the shareholders of the Company, no further awards will be granted under the 2018 Stock Option Plan; however, shares may be purchased via option exercise by the holders of any outstanding options previously issued under the 2018 Stock Option Plan.

On March 29, 2020, the Board adopted the 2020 Omnibus Plan, which was approved by the shareholders of the Company at the annual and special meeting of shareholders held on June 25, 2020. The 2020 Omnibus Plan provides for grants of stock options, share appreciation rights, restricted shares, RSUs and other share-based or cash-based awards, which are subject to terms as determined by the Compensation Committee of the Board (the “Compensation Committee”), and awards may be granted to eligible employees, non-employee directors and consultants. The 2020 Omnibus Plan terminated the Company’s ability to grant equity awards under the 2018 Stock Option Plan and RSUs under the Employment Inducement Award Plan.

Options represent the right to purchase Company common shares on the date of exercise at a stated exercise price. The exercise price of an option generally must be at least equal to the fair market value of the Company common shares on the date of grant. Vesting conditions for grants of options are determined by the Compensation Committee. The typical vesting for stock option grants is quarterly vesting over three to five years. The maximum term of options granted under the 2020 Omnibus Plan is seven years. Participants under the 2020 Omnibus Plan are eligible to be granted options to purchase shares at an exercise price established upon approval of the grant by the Compensation Committee. When options are granted, the exercise price is, with respect to a particular date, the closing price as reported by the TSX or the Nasdaq and, if the shares are not traded on the TSX or the Nasdaq, any other stock exchange on which the Company’s common shares are traded (as selected by the Compensation Committee in good faith taking into account applicable legal and tax requirements) on the immediately preceding trading day (the “Fair Market Value”). The 2020 Omnibus Plan does not authorize grants of options with an exercise price below the Fair Market Value.

The following is a summary of the changes in options:


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2023	$	10.57	5,350,600	0.73
Issuance of options	2.96		188,317

Cancellation, forfeiture and expiry of options	7.75		(3,435,716)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Exercisable as of December 31, 2023	$	15.89	1,864,732	1.29


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2022	$	7.75	8,939,330	2.70
Issuance of options	4.20		113,947
Exercise of options	2.79		(2,735,985)
Cancellation, forfeiture and expiry of options	5.74		(966,692)
Balance as of December 31, 2022	$	10.57	5,350,600	0.73
Exercisable as of December 31, 2022	$	11.48	3,867,887	0.66

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.

For the years ended December 31, 2023 and 2022, the fair value per option at grant date was C$2.07 and C$2.94, respectively. The fair value of the options issued during the year was determined using the Black-Scholes option pricing model, using the following inputs:


	2023	2022
Share price at grant date (per share)	C$2.96	C$4.20
Exercise price (per option)	C$2.96	C$4.20
Risk-free interest rate(i)	3.22%	3.14%
Expected life of options (in years)(i)	7	7
Expected annualized volatility(i)	73%	73%
Expected dividend yield	—	—
Weighted average Black-Scholes value at grant date (per option)	C$2.07	C$2.94
Forfeiture rate	—	—

(i)The expected life of the awards represents the period of time options are expected to be outstanding and is estimated considering vesting terms and employees’ and non-employees’ historical exercise and, where relevant, post-vesting employment termination behavior. Volatility was estimated by using the historical volatility of the Company’s share price, adjusted for the Company’s expectation of volatility going forward. The risk-free interest rate was based on the Bank of Canada government bonds with a remaining term equal to the expected life of the options at the grant date.

The following table summarizes stock options outstanding:


	Options outstanding as of December 31,
	2023	2022	2021
2020 Omnibus Plan	702,264	2,788,947	2,900,000
2018 Stock Option Plan	1,400,937	1,422,069	1,550,074
2015 Stock Option Plan	—	1,139,584	4,489,256
Total stock options outstanding	2,103,201	5,350,600	8,939,330

(c)Restricted share units

RSUs are granted under the 2020 Omnibus Plan. RSUs represent an equivalent amount of Company common shares on the date of issuance at fair value. Fair value is determined using the closing price of the trading day immediately preceding the date of grant. RSUs issued under the 2020 Omnibus Plan typically vest over a three-year period following the grant date and have no performance requirements.

The following is a summary of the changes in RSUs:


	Weighted average grant date fair value (C$)(iii)		Number of RSUs
Balance as of January 1, 2023	$	4.63	5,725,470
Granted(i)	2.64		3,292,586
Vested and issued	5.00		(1,041,097)
Cancellation and forfeitures	3.60		(595,418)
Balance as of December 31, 2023	$	3.77	7,381,541


	Weighted average grant date fair value (C$)(iii)		Number of RSUs
Balance as of January 1, 2022	$	9.22	1,225,870
Granted(i)(ii)	4.27		6,140,492
Vested and issued	7.40		(1,151,292)
Cancellation and forfeitures	5.08		(489,600)
Balance as of December 31, 2022	$	4.63	5,725,470

(i)RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three or five year “cliff-period.” All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

(ii)Equity grants for 2020, 2021 and 2022 were held back for certain executives of the Company in connection with ongoing investigations by the SEC and the OSC, which were subsequently settled on October 24, 2022. On August 5, 2022, the Compensation Committee approved the release of these held-back equity grants conditioned upon settlement of the SEC and OSC investigations. These RSUs vest in equal installments over a period of three years from what would have been their original grant dates had the grants not been withheld.

(iii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

(d)Deferred share units

On August 10, 2019, the Company established the DSU Plan pursuant to which its non-executive directors receive DSUs for Board services. The DSU Plan is designed to promote a greater alignment of long-term interests between non-executive directors and shareholders. The number of DSUs granted under the DSU Plan (including fractional DSUs) is determined by dividing the amount of remuneration payable by the closing price as reported by the TSX for awards made prior to 2022 and as reported by Nasdaq for awards made in 2022 and 2023 on the trading day immediately preceding the date of grant. DSUs are payable at the time a non-executive director ceases to hold the office of director for any reason and are settled by a lump-sum cash payment, in accordance with the terms of the DSU Plan, based on the fair value of the DSUs at such time. The fair value of the cash payout is determined by multiplying the number of DSUs vested at the payout date by the closing price as reported by the TSX for awards made prior to 2022 and as reported by Nasdaq for awards made in 2022 and 2023 on the trading day immediately preceding the payout date. The fair value of the cash payout is determined at each reporting date based on the fair value of the Company’s common shares at the reporting date and is recorded within other liabilities.

The following is a summary of the changes in DSUs:


	Financial liability		Number of DSUs
Balance as of January 1, 2023	$	674	265,732
Granting and vesting of DSUs	450		255,947

Gain on revaluation	(32)		—
Balance as of December 31, 2023	$	1,092	521,679


	Financial liability		Number of DSUs
Balance as of January 1, 2022	$	408	104,442
Granting and vesting of DSUs	443		161,290

Loss on revaluation	(177)		—
Balance as of December 31, 2022	$	674	265,732

(e)Liability-classified awards

During the year ended December 31, 2022, the Compensation Committee conditionally approved the grant to one of the Company’s former executives of share-based compensation awards for a fixed monetary amount, but a variable number of common shares. These awards were liability-classified until the number of common shares was determined.


	Financial liability
Balance as of January 1, 2022	$	—
Grants	597
Transfers to equity awards	(597)

Balance as of December 31, 2022	$	—

During the year ended December 31, 2023, there was no liability-classified award activity.

Inventory, net (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory, net is comprised of the following items:


	As of December 31,
	2023		2022
Raw materials	$	4,795	$	7,421
Work-in-progress	10,593		15,646
Finished goods	14,819		13,503
Supplies and consumables	288		989
Total	$	30,495	$	37,559

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Valuation Allowance [Line Items]
Loss from discontinued operations	$ (4,114)	$ (13,556)	$ (269,125)
Taxes payable, current	64	32,956	105
Taxes receivable, current	3,374	40	543
Valuation allowance	216,241	214,199
Research Tax Credit Carryforward
Valuation Allowance [Line Items]
Tax credit carryforward	683
Canada
Valuation Allowance [Line Items]
Operating loss carryforwards	253,521	216,120
Untied States
Valuation Allowance [Line Items]
Operating loss carryforwards	144,219	134,593
Israel
Valuation Allowance [Line Items]
Operating loss carryforwards	20,794	18,739
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset
Valuation Allowance [Line Items]
Valuation allowance increase (decrease)	2,042	(10,577)
Altria Warrant
Valuation Allowance [Line Items]
Capital gain on relinquishment of warrant		479,800
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Valuation Allowance [Line Items]
Loss from discontinued operations	$ (4,114)	$ (13,556)	$ (269,125)

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease, extension term	10 years
Operating lease, impairment loss		$ 1,986
General and Administrative Expense
Lessee, Lease, Description [Line Items]
Depreciation expense on right-of-use assets	$ 455	$ 839	$ 1,386
Land
Lessee, Lease, Description [Line Items]
Operating lease, term	15 years
Minimum \| Office Premises and Equipment
Lessee, Lease, Description [Line Items]
Operating lease, term	3 years
Maximum \| Office Premises and Equipment
Lessee, Lease, Description [Line Items]
Operating lease, term	6 years

Restructuring

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Restructuring

In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, which are expected to result in the Company maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the Company’s products, while seeking to sell and lease back all or some of the Peace Naturals Campus or to lease certain portions of the Peace Naturals Campus to third parties. In the third quarter of 2023, the Board approved revisions to the Realignment to wind down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”), list the Cronos Fermentation facility for sale, and implement additional organization-wide cost reductions as the Company continues its Realignment initiatives. During the third quarter of 2023, the Company performed an assessment under ASC 360, Property Plant and Equipment, of the recovery of the carrying value of the Canada asset group, which includes Cronos Fermentation, and determined the carrying value of the asset group was recoverable. As of December 31, 2023, Cronos Fermentation did not meet the criteria to be classified as held-for-sale.

During the year ended December 31, 2023, the Company incurred $1,524 of restructuring costs in its continuing operations in connection with the Realignment. During the year ended December 31, 2022, the Company recognized $3,545 of restructuring costs in continuing operations in connection with the Realignment. Charges related thereto include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. During the year ended December 31, 2023, as a result of the decision to wind down operations at Cronos Fermentation, the Company recognized an inventory write-down of $805 related to certain obsolete raw materials. Restructuring costs and inventory write-downs incurred in the Company’s discontinued operations during the years ended December 31, 2023 and 2022 is presented in Note 2 “Discontinued Operations”.

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2023 and 2022:


	As of January 1, 2023		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150


	As of January 1, 2022		Expenses		Payments/Write-offs		As of December 31, 2022
Employee Termination Benefits	$	—	$	1,883	$	(1,480)	$	403

Other Restructuring Costs	—		1,662		(1,641)		21
Total	$	—	$	3,545	$	(3,121)	$	424

Share-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 8,756	$ 15,008	$ 9,844
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	1,175	6,778	7,604
Restricted Stock Units (RSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	7,581	7,633	2,240
Liability Classified Awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 0	$ 597	$ 0

Derivative Liabilities

12 Months Ended

Dec. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liabilities

On March 8, 2019, the Company closed the previously announced investment in the Company (the “Altria Investment”) by Altria Group Inc. (“Altria”), pursuant to a subscription agreement dated December 7, 2018. As of the closing date of the Altria Investment, the Altria Investment consisted of 149,831,154 common shares of the Company and one warrant of the Company (the “Altria Warrant”), issued to a wholly owned subsidiary of Altria. As of the closing date of the Altria Investment, Altria beneficially held an approximate 45% ownership interest in the Company (calculated on a non-diluted basis). On December 16, 2022, Altria notified the Company that it was irrevocably relinquishing all of its rights, title and interest in the Altria Warrant, effective immediately. As a result, the Company’s liability associated with the Altria Warrant was reduced to nil, with the change recorded to gain on revaluation of derivative liabilities for the year ended December 31, 2022.

Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the “Investor Rights Agreement”), the Company granted Altria certain rights, among others, summarized in this note.

The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable.

a.The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership with Ginkgo, (refer to Note 10 “Commitments and Contingencies”), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Collaboration Agreement will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.

b.In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).

The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the 10 full days preceding such exercise by Altria; provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities on the Company’s consolidated balance sheet.

As of December 31, 2023, Altria beneficially held 156,573,537 of the Company’s common shares, an approximate 41.1% ownership interest in the Company (calculated on a non-diluted basis).

Reconciliations of the carrying amounts of the derivative liability are presented below:


	As of January 1, 2023		Loss (gain) on revaluation		Foreign exchange effect		As of December 31, 2023

Pre-emptive Rights	—		100		2		102
Top-up Rights	15		(15)		—		—
	$	15	$	85	$	2	$	102


	As of January 1, 2022		Gain on revaluation		Foreign exchange effect		As of December 31, 2022
Altria Warrant	$	13,720	$	(13,431)	$	(289)	$	—
Pre-emptive Rights	180		(179)		(1)		—
Top-up Rights	475		(450)		(10)		15
	$	14,375	$	(14,060)	$	(300)	$	15

Fluctuations in the expected life of the derivative instruments and the Company’s share price are primary drivers for the changes in the derivative valuations during each reporting period. As the period of time the derivative liability is expected to be outstanding decreases and the share price decreases, the fair value typically decreases for each related derivative instrument. Weighted-average expected life and share price are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments.

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:


	As of December 31, 2023
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.77	$2.77
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	3.99%	4.76%
Weight average expected life (in years)(ii)	1.75	0.60
Expected annualized volatility(iii)	60%	58%
Expected dividend yield	—%	—%


	As of December 31, 2022
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$3.44	$3.44
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	4.14%	4.28%
Weight average expected life (in years)(ii)	0.25	0.59
Expected annualized volatility(iii)	73%	73%
Expected dividend yield	—%	—%

(i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of December 31, 2023 and December 31, 2022, the risk-free interest rate uses a range of approximately 3.99% to 4.82% and 3.81% to 4.37%, respectively, for the Pre-emptive Rights and Top-up Rights.

(ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of December 31, 2023 and December 31, 2022, the expected life uses a range of approximately 0.50 years to 1.75 years and 0.25 years to 2.75 years, respectively.

(iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Financial Instruments - Schedule of Fair Value of Assets on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 35,251	$ 70,993	$ 118,392
Derivative liabilities	102	15
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	669,291	764,644
Short-term investments	192,237	113,077
Other investments	9,601	21,993
Derivative liabilities	102	15
Level 1 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	669,291	764,644
Short-term investments	192,237	113,077
Other investments	9,601	21,993
Derivative liabilities	0	0
Level 2 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	0	0
Level 3 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	$ 102	$ 15

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Property, Plant & Equipment, Useful Lives (Details)	Dec. 31, 2023
Building and leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	15 years
Building and leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	20 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	5 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	7 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant & equipment, useful life	5 years

Consolidated Statements of Changes in Shareholders’ Equity - USD ($) $ in Thousands	Total	Common Shares	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	$ 1,708,168	$ 569,260	$ 34,596	$ 1,064,509	$ 42,999	$ (3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		11,764,381
Activities relating to share-based compensation	(2,254)	$ 7,288	2,671	(12,213)
Share issuance pursuant to research and development milestone (in shares)		2,934,980
Share issuance pursuant to research and development milestones	17,374	$ 17,374
Accelerated restricted share units vesting out-of-period adjustment	0	4,802	(4,802)
Top-up rights out-of-period adjustment	0	$ (3,227)		3,227
Net loss	(397,204)			(396,107)		(1,097)
Foreign exchange gain on translation	8,192				6,866	1,326
Ending balance (in shares) at Dec. 31, 2021		374,952,693
Ending balance at Dec. 31, 2021	1,334,276	$ 595,497	32,465	659,416	49,865	(2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		1,464,822
Activities relating to share-based compensation	14,834	$ 4,617	10,217
Share issuance pursuant to research and development milestone (in shares)		4,157,888
Share issuance pursuant to research and development milestones	11,204	$ 11,204
Net loss	(168,734)			(168,734)
Foreign exchange gain on translation	$ (50,616)				(50,662)	46
Ending balance (in shares) at Dec. 31, 2022	380,575,403	380,575,403
Ending balance at Dec. 31, 2022	$ 1,140,964	$ 611,318	42,682	490,682	(797)	(2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		723,450
Activities relating to share-based compensation	8,174	$ 2,407	5,767
Net loss	(74,553)			(73,963)		(590)
Foreign exchange gain on translation	$ 21,539				21,475	64
Ending balance (in shares) at Dec. 31, 2023	381,298,853	381,298,853
Ending balance at Dec. 31, 2023	$ 1,096,124	$ 613,725	$ 48,449	$ 416,719	$ 20,678	$ (3,447)

Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue, before excise taxes	$ 120,270	$ 109,301	$ 79,612
Excise taxes	(33,029)	(22,552)	(15,051)
Net revenue	87,241	86,749	64,561
Cost of sales	74,527	71,313	70,193
Inventory write-down	805	0	11,961
Gross profit	11,909	15,436	(17,593)
Operating expenses
Sales and marketing	22,701	18,046	20,917
Research and development	5,843	13,131	21,841
General and administrative	49,475	67,674	90,919
Restructuring costs	1,524	3,545	0
Share-based compensation	8,756	15,008	9,844
Depreciation and amortization	5,044	5,967	4,413
Impairment loss on goodwill and indefinite-lived intangible assets	0	0	37
Impairment loss on long-lived assets	3,366	3,493	126,405
Total operating expenses	96,709	126,864	274,376
Operating loss	(84,800)	(111,428)	(291,969)
Other income (expense)
Interest income, net	51,235	22,514	9,068
Gain (loss) on revaluation of derivative liabilities	(85)	14,060	151,360
Share of income (loss) from equity method investments	1,583	3,114	(6,313)
Gain (loss) on revaluation of financial instruments	(12,042)	14,739	8,611
Impairment loss on other investments	(23,350)	(61,392)	0
Foreign currency transaction loss	(7,324)	(2,286)	0
Other, net	1,114	(324)	733
Total other income (expense)	11,131	(9,575)	163,459
Loss before income taxes	(73,669)	(121,003)	(128,510)
Income tax expense (benefit)	(3,230)	34,175	(431)
Loss from continuing operations	(70,439)	(155,178)	(128,079)
Loss from discontinued operations	(4,114)	(13,556)	(269,125)
Net loss	(74,553)	(168,734)	(397,204)
Net loss attributable to non-controlling interest	(590)	0	(1,097)
Net loss attributable to Cronos Group	(73,963)	(168,734)	(396,107)
Comprehensive income (loss)
Net loss	(74,553)	(168,734)	(397,204)
Foreign exchange gain (loss) on translation	21,539	(50,616)	8,192
Comprehensive loss	(53,014)	(219,350)	(389,012)
Comprehensive income (loss) attributable to non-controlling interest	(526)	46	229
Comprehensive loss attributable to Cronos Group	$ (52,488)	$ (219,396)	$ (389,241)
Net loss per share
Basic - continuing operations (in dollars per share)	$ (0.18)	$ (0.41)	$ (0.34)
Diluted - continuing operations (in dollars per share)	(0.18)	(0.41)	(0.34)
Basic - discontinued operations (in dollars per share)	(0.01)	(0.04)	(0.73)
Diluted - discontinued operations (in dollars per share)	(0.01)	(0.04)	(0.73)
Basic - total (in dollars per share)	(0.19)	(0.45)	(1.07)
Diluted - total (in dollars per share)	$ (0.19)	$ (0.45)	$ (1.07)

Investments - Narrative (Details) $ / shares in Units, ₪ in Thousands, $ in Thousands		3 Months Ended					12 Months Ended
	Jun. 14, 2021 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 ILS (₪)	Feb. 28, 2022	Dec. 16, 2021 seat	Dec. 15, 2021 seat	Oct. 12, 2021	Sep. 14, 2021 AUD ($)
Variable Interest Entity [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares	$ 0.0001
Percentage of ownership after transaction	10.50%
Payments to acquire other investments	$ 110,392,000
Impairment charges							$ 23,350,000	$ 61,392,000	$ 0
Gain (loss) on revaluation of financial instruments							(12,042,000)	14,739,000	$ 8,611,000
Other investments		$ 35,251,000	$ 70,993,000				$ 35,251,000	$ 70,993,000
Pharmacann
Variable Interest Entity [Line Items]
Ownership interest		5.90%	6.30%				5.90%	6.30%		5.90%	6.40%
Pharmacann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	473,787
Cronos GrowCo
Variable Interest Entity [Line Items]
Ownership interest		50.00%	50.00%				50.00%	50.00%		50.00%
Cronos GrowCo \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Impairment loss						$ 0
Cannasoul Analytics Ltd. \| Variable Interest Entity, Not Primary Beneficiary \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Variable Interest Entity [Line Items]
Collaborative arrangement, percentage of profits to be received		70.00%					70.00%			70.00%
Collaborative arrangement, profits to be received, maximum percentage of amounts advanced		150.00%					150.00%			150.00%
Collaborative arrangement, percentage of profits to be received, triggering event, subsequent to maximum percentage of amounts advanced being met		50.00%					50.00%			50.00%
Cannasoul Analytics Ltd. \| Variable Interest Entity, Not Primary Beneficiary \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Cannasoul Collaboration Loan \| Loans Receivable
Variable Interest Entity [Line Items]
Collaboration agreement, amount of advances		$ 2,664,000					$ 2,664,000			₪ 8,297
Collaborative arrangement, term of agreement							2 years
Interest rate		3.50%					3.50%			3.50%
Pharmacann
Variable Interest Entity [Line Items]
Impairment charges		$ 23,350,000	$ 21,182,000	$ 28,972,000	$ 11,238,000		$ 23,350,000	$ 61,392,000
Pharmacann \| LivWell Holdings, Inc.
Variable Interest Entity [Line Items]
Merger agreement, threshold ownership percentage														6.00%
Vitura
Variable Interest Entity [Line Items]
Impairment charges							0	0
Unsecured loan															$ 1,500
Ownership interest												10.00%	31.00%
Number of seats on board of directors \| seat												0	2
Gain (loss) on revaluation of financial instruments							(12,096,000)	14,739,000
Other investments		$ 9,601,000	$ 21,993,000				$ 9,601,000	$ 21,993,000

Consolidated Balance Sheet - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 669,291	$ 764,644
Short-term investments	192,237	113,077
Accounts receivable, net	13,984	23,113
Interest receivable	10,012	2,469
Other receivables	6,341	3,298
Current portion of loans receivable, net	5,541	8,890
Inventory, net	30,495	37,559
Prepaids and other current assets	5,405	7,106
Total current assets	933,306	960,156
Equity method investments, net	19,488	18,755
Other investments	35,251	70,993
Non-current portion of loans receivable, net	69,036	72,345
Property, plant and equipment, net	59,468	60,557
Right-of-use assets	1,356	2,273
Goodwill	1,057	1,033
Intangible assets, net	21,078	26,704
Other	45	193
Total assets	1,140,085	1,213,009
Current liabilities
Accounts payable	12,130	11,163
Income taxes payable	64	32,956
Accrued liabilities	27,736	22,268
Current portion of lease obligation	994	1,330
Derivative liabilities	102	15
Current portion due to non-controlling interests	373	384
Total current liabilities	41,399	68,116
Non-current portion due to non-controlling interests	1,003	1,383
Non-current portion of lease obligation	1,559	2,546
Total liabilities	43,961	72,045
Shareholders’ equity
Share capital (authorized for issue as of December 31, 2023 and 2022: unlimited; shares outstanding as of December 31, 2023 and 2022: 381,298,853 and 380,575,403, respectively)	613,725	611,318
Additional paid-in capital	48,449	42,682
Retained earnings	416,719	490,682
Accumulated other comprehensive income (loss)	20,678	(797)
Total equity attributable to shareholders of Cronos Group	1,099,571	1,143,885
Non-controlling interests	(3,447)	(2,921)
Total shareholders’ equity	1,096,124	1,140,964
Total liabilities and shareholders’ equity	$ 1,140,085	$ 1,213,009

Property, Plant and Equipment, net

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, net

Property, plant and equipment, net

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2023		2022
Cost
Land		$	2,764	$	2,556
Building and leasehold improvements		168,498		177,095
Machinery and equipment		21,322		19,130
Furniture and fixtures		3,385		5,345
Construction in progress		3,269		841
Less: accumulated depreciation		(30,707)		(35,347)
Less: accumulated impairment charges		(109,063)		(109,063)
Property, plant and equipment, net		$	59,468	$	60,557

For the years ended December 31, 2023, 2022 and 2021, depreciation expense on property, plant and equipment was $3,913, $8,667 and $11,668, respectively, and was included in cost of sales as well as depreciation and amortization in operating expenses on the consolidated statements of net loss and comprehensive loss.

Impairment of Long-lived Assets

During the third quarter of 2023, as a result of the Company’s decision to wind down the operations at Cronos Fermentation, the Company performed an assessment of the recovery of the carrying value of the Canada asset group and determined the carrying value of the asset group was recoverable.

During the first quarter of 2022, the Company recognized an impairment charge of $1,507 related to leasehold improvements and other office equipment that it planned to include in any potential sublease agreement of the Company’s corporate headquarters in Toronto, Ontario, Canada. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. The impairment charge was recognized as impairment loss on long-lived assets on the consolidated statements of net loss and comprehensive loss.

During the fourth quarter of 2021, the Company concluded that indicators of impairment were present with respect to its Canadian asset group in connection with the previously anticipated wind-down and closure of the Company’s facility in Stayner, Ontario. As a result, the Company compared the sum of the undiscounted future cash flows attributable to the Canadian asset group to their respective carrying amounts and recorded a non-cash impairment charge on long-lived assets of $113,917 as the difference between the carrying amount of the asset group and its estimated fair value for the year ended December 31, 2021, in the consolidated statements of net loss and comprehensive loss.

Held-for-sale Assessments

The Company evaluated both the Peace Naturals Campus and the Cronos Fermentation facility for held-for-sale classification as of December 31, 2023, and, as a result of the assessments, determined that neither asset group met the criteria to be classified as held-for-sale as of December 31, 2023. The Peace Naturals Campus failed the criteria, as the facility is not immediately available for sale in its present condition due to ongoing construction related to the condition the facility must be in for the proposed leaseback to occur. The Cronos Fermentation facility failed the criteria as it was determined it was not probable to sell the property within one year, and the property was not being marketed at a reasonable price in relation to its fair value, as the property is currently being marketed unpriced.

Financial Instruments

12 Months Ended

Dec. 31, 2023

Risks and Uncertainties [Abstract]

Financial Instruments

(a)Fair value measurement

The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:

•Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.

•Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	As of December 31, 2023
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	669,291	$	—	$	—	$	669,291
Short-term investments	192,237		—		—		192,237
Other investments(i)	9,601		—		—		9,601
Derivative liabilities	—		—		102		102


	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	764,644	$	—	$	—	$	764,644
Short-term investments	113,077		—		—		113,077
Other investments(i)	21,993		—		—		21,993
Derivative liabilities	—		—		15		15

(i)As of December 31, 2023 and December 31, 2022, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “Investments” for additional information.

There were no transfers between fair value categories during the periods presented.

The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	As of December 31, 2023
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	25,650	25,650


	As of December 31, 2022
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	49,000	49,000

(i)On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell pursuant to which PharmaCann acquired LivWell. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of December 31, 2023 and December 31, 2022, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 5.9% and 6.3%, respectively. See Note 4 “Investments”.

There were no transfers between fair value categories during the periods presented.

(b)Financial risks

The Company’s activities expose it to a variety of financial risks, including credit risk, liquidity risk, market risk, interest rate risk, and foreign currency rate risk.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $966,442 and $987,836 as of December 31, 2023 and December 31, 2022, respectively.

(i)Accounts receivable

The Company had accounts receivable of $13,984 and $23,113 as of December 31, 2023 and December 31, 2022, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan, and a failure to make contractual payments for a period of greater than 120 days past due. As of December 31, 2023 and 2022, the Company had $3 and $219, respectively, in expected credit losses on receivables from contracts with customers.

As of December 31, 2023, the Company has assessed that there is a concentration of credit risk as 37% of the Company’s accounts receivable were due from one customer with an established credit history with the Company. As of December 31, 2022, 55% of the Company’s accounts receivable were due from three customers with an established credit history with the Company.

The Company sells products through a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenues. During the year ended December 31, 2023, the Company earned a total net revenue before excise taxes of $79,503 from three major customers, together accounting for 66% of the Company’s total net revenue before excise taxes. During the year ended December 31, 2022, the Company earned a total net revenue before excise taxes of $63,509 from three major customers, together accounting for 55% of the Company’s total net revenue before excise taxes. During the year ended December 31, 2021, the Company earned a total net revenue before excise taxes of $41,603 from three major customers, accounting for 56% of the Company’s total net revenues before excise taxes.

(ii) Cash and cash equivalents, short-term investments, and other receivables

The Company held cash and cash equivalents of $669,291 and $764,644 as of December 31, 2023 and December 31, 2022, respectively. The short-term investments and related interest receivable of $192,237 and $113,077 as of December 31, 2023 and December 31, 2022, respectively, represent short-term investments with a maturity of less than a year and accrued interest. The cash and cash equivalents and short-term investments, including guaranteed investment certificates and bankers’ acceptances, are held with central banks and financial institutions that are highly rated. In addition to interest receivable, other receivables include sales taxes receivable from the government. As such, the Company has assessed an insignificant loss allowance on these financial instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due and arises principally from the Company’s accounts payable. The Company had trade accounts payable of $8,887 and $8,599 as of December 31, 2023 and December 31, 2022, respectively, included in accounts payable on the consolidated balance sheet. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. As of December 31, 2023, the Company has assessed a concentration of risk of vendors as 26% of accounts payable were due to one vendor. As of December 31, 2022, the Company has assessed a concentration risk of vendors as 27% of accounts payable due to one vendor.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to market risk in divesting its investments, such that unfavorable market conditions could result in dispositions of investments at less than their carrying amounts. Further, the revaluation of securities classified as fair value through net income could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s results of operations, unless these would flow through other comprehensive income.

The Company manages risk by having a portfolio of securities from multiple issuers, such that the Company was not materially exposed to any one issuer.

Interest rate risk

Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of income and expense recorded on the cash equivalents and short-term investments, and the market value of all interest-earning assets, other than those that possess a short term to maturity. A 10% change in the interest rate in effect on December 31, 2023 would not have a material effect on the fair value of our cash equivalents and short-term investments as the majority of the portfolio had a maturity date of three months or less. A 10% change in the interest rate in effect for 2023 would have an effect of $5.4 million on interest income, net earned on our cash equivalents and short-term investments. A 10% change in the interest rate in effect on December 31, 2022, would not have a material effect on (i) fair value of the cash equivalents and short-term investments as the majority of the portfolio had a maturity date of three months or less, or (ii) interest income, net. Management continues to monitor external interest rates and revise the Company’s investment strategy as a result.

During the years ended December 31, 2023 and December 31, 2022, the Company had net interest income of $51,235 and $22,514, respectively. During the year ended December 31, 2023, the Company’s average variable interest rate increased approximately 1.45%. During the year ended December 31, 2022, the Company’s average variable interest rate increased approximately 3.50%.

Foreign currency risk

Currency rate risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on investments in equity investments denominated in A$ and C$, and other assets and liabilities denominated in A$ and C$. The Company is further exposed to this risk through subsidiaries operating in Israel and the U.S. as the Company’s functional currency is in Canadian dollars. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk. As such, the Company’s financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.

As of December 31, 2023 and December 31, 2022, the Company had foreign currency gain (loss) on translation of $21,539 and $(50,616), respectively. A 10% change in the exchange rates for the foreign currencies would affect the carrying amounts of net assets by approximately $97,678 and $77,414 as of December 31, 2023 and December 31, 2022, respectively.

Goodwill and Intangible Assets, net - Impairment Charges on Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	$ (11,008)
Ending balance	(14,696)	$ (11,008)
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(73,650)	(74,308)	$ (6,053)
Impairment charges	(3,366)	(76)	(68,389)
Foreign exchange effect	(322)	734	134
Ending balance	(77,338)	(73,650)	(74,308)
Lord Jones brand
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(62,500)	(62,500)	(5,000)
Impairment charges	0	0	(57,500)
Ending balance	(62,500)	(62,500)	(62,500)
Trademarks
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	(142)	(142)	0
Impairment charges	0	0	(142)
Ending balance	(142)	(142)	(142)
Software
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(76)	(4)	0
Impairment charges	0	76	4
Foreign exchange effect	(2)	4	0
Ending balance	(78)	(76)	(4)
Health Canada licenses
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(6,498)	(6,910)	(1,053)
Impairment charges	0	0	5,951
Foreign exchange effect	(152)	412	94
Ending balance	(6,650)	(6,498)	(6,910)
Ginkgo exclusive licenses
Finite-lived Intangible Assets [Roll Forward]
Beginning balance	(4,434)	(4,752)	0
Impairment charges	3,366	0	4,792
Foreign exchange effect	(168)	318	40
Ending balance	$ (7,968)	$ (4,434)	$ (4,752)

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 31, 2023	Feb. 23, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St., Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Financial Statement Error Correction [Flag]	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 391,676,759
Entity Common Stock, Shares Outstanding (in shares)		381,298,853
Documents Incorporated by Reference	Certain information required by Part III of this Annual Report on Form 10-K will either be incorporated into this Annual Report on Form 10-K by reference to the registrant’s definitive proxy statement for its 2024 Annual Meeting of Shareholders, or will be included in an amendment to this Annual Report on Form 10-K to be filed no later than 120 days after the registrant's fiscal year ended December 31, 2023.
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001656472

Restructuring - Restructuring Activity (Details) - Realignment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 424	$ 0
Expenses	1,524	3,545
Payments/Write-offs	(1,798)	(3,121)
Restructuring Reserve, Ending Balance	150	424
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	403	0
Expenses	1,371	1,883
Payments/Write-offs	(1,624)	(1,480)
Restructuring Reserve, Ending Balance	150	403
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	21	0
Expenses	153	1,662
Payments/Write-offs	(174)	(1,641)
Restructuring Reserve, Ending Balance	$ 0	$ 21

Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Cost	$ 1,057	$ 1,033
Accumulated impairment charges	0	0
Net	1,057	1,033
Peace Naturals
Goodwill [Line Items]
Cost	1,057	1,033
Accumulated impairment charges	0	0
Net	$ 1,057	$ 1,033

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Leases - Schedule of Lease Cost and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lease cost
Operating lease cost	$ 685	$ 1,107	$ 1,693
Short-term lease cost	0	0	10
Total lease cost	685	1,107	1,703
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	1,124	1,441	1,706
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	$ 0	$ 0	$ 0
Weighted-average remaining lease term (years) – operating leases	3 years 7 months 6 days	4 years 3 months 18 days	4 years 8 months 12 days
Weighted-average discount rate – operating leases	7.62%	7.39%	7.62%

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Accrued payroll and related expenses	$ 8,970	$ 11,492
Accrued professional fees	2,525	2,414
Accrued taxes	11,695	4,132
Other accrued expenses	4,546	4,230
Total accrued liabilities	$ 27,736	$ 22,268

Share-based Compensation - Fair Value of Options Issued (Details) - Stock options - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in Canadian dollars per share)	$ 2.96	$ 4.2
Exercise price (per option) (in Canadian dollars per share)	$ 2.96	$ 4.2
Risk-free interest rate	3.22%	3.14%
Expected life of options	7 years	7 years
Expected annualized volatility	73.00%	73.00%
Expected dividend yield	0.00%	0.00%
Weighted average Black-Scholes value at grant date (per option) (in Canadian dollars per share)	$ 2.07	$ 2.94
Forfeiture rate	0.00%	0.00%

Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (73,669)	$ (121,003)	$ (128,510)
Effective income tax rate	26.50%	26.50%	26.50%
Expected income tax benefit	$ (19,522)	$ (32,066)	$ (34,055)
Non-taxable income (loss)	1,077	(2,140)	39
Non-deductible share-based compensation	525	1,198	1,667
Non-deductible expenses	459	836	53
Non-deductible transaction costs	351	1,625	2,917
Effect of provincial tax rate difference	(9)	(15)	(1)
Effect of tax rates outside of Canada	816	1,848	(1,869)
Effect of change in tax rates	4,601	11,041	0
Fair value gain (loss) on financial liabilities	23	(3,726)	(40,111)
Changes in valuation allowance	7,930	(10,466)	70,453
Capital gain on financial liabilities	106	66,193	0
Other	413	(153)	476
Income tax expense (benefit), net	$ (3,230)	$ 34,175	$ (431)

Property, Plant and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

5 to 7 years

Furniture and fixtures

5 years

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2023		2022
Cost
Land		$	2,764	$	2,556
Building and leasehold improvements		168,498		177,095
Machinery and equipment		21,322		19,130
Furniture and fixtures		3,385		5,345
Construction in progress		3,269		841
Less: accumulated depreciation		(30,707)		(35,347)
Less: accumulated impairment charges		(109,063)		(109,063)
Property, plant and equipment, net		$	59,468	$	60,557

Restructuring (Tables)

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Schedule of Plan Information and Restructuring-Related Costs

The following tables summarize the Company’s discontinued operations restructuring activity for the years ended December 31, 2023 and 2022:


	Accrual as of January 1, 2023		Expenses		Payments/Write-offs		Accrual as of December 31, 2023
Employee Termination Benefits	$	—	$	431	$	(431)	$	—

Other Restructuring Costs	—		92		(92)		—
Total	$	—	$	523	$	(523)	$	—


	Accrual as of January 1, 2022		Expenses		Payments/Write-offs		Accrual as of December 31, 2022
Employee Termination Benefits	$	—	$	1,788	$	(1,788)	$	—


Total	$	—	$	1,788	$	(1,788)	$	—

The following table summarizes the Company’s restructuring activity for the years ended December 31, 2023 and 2022:


	As of January 1, 2023		Expenses		Payments/Write-offs		As of December 31, 2023
Employee Termination Benefits	$	403	$	1,371	$	(1,624)	$	150

Other Restructuring Costs	21		153		(174)		—
Total	$	424	$	1,524	$	(1,798)	$	150


	As of January 1, 2022		Expenses		Payments/Write-offs		As of December 31, 2022
Employee Termination Benefits	$	—	$	1,883	$	(1,480)	$	403

Other Restructuring Costs	—		1,662		(1,641)		21
Total	$	—	$	3,545	$	(3,121)	$	424

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 87,241	$ 86,749	$ 64,561
Canada
Segment Reporting Information [Line Items]
Revenue	64,702	56,233	50,294
Israel
Segment Reporting Information [Line Items]
Revenue	21,134	30,516	13,376
Other countries
Segment Reporting Information [Line Items]
Revenue	1,405	0	891
Cannabis flower
Segment Reporting Information [Line Items]
Revenue	62,070	63,593	55,194
Cannabis extracts
Segment Reporting Information [Line Items]
Revenue	24,569	22,522	8,807
Other
Segment Reporting Information [Line Items]
Revenue	$ 602	$ 634	$ 560

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Stock-based Compensation Expense

The following table summarizes the total share-based compensation associated with the Company’s stock options and RSUs:


	Year ended December 31,
	2023		2022		2021
Stock options	$	1,175	$	6,778	$	7,604
RSUs	7,581		7,633		2,240
Liability-classified awards(i)	—		597		—
Total share-based compensation	$	8,756	$	15,008	$	9,844

Summary of the Changes in Options

The following is a summary of the changes in options:


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2023	$	10.57	5,350,600	0.73
Issuance of options	2.96		188,317

Cancellation, forfeiture and expiry of options	7.75		(3,435,716)
Balance as of December 31, 2023	$	14.50	2,103,201	1.84
Exercisable as of December 31, 2023	$	15.89	1,864,732	1.29


	Weighted average exercise price (C$)(i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2022	$	7.75	8,939,330	2.70
Issuance of options	4.20		113,947
Exercise of options	2.79		(2,735,985)
Cancellation, forfeiture and expiry of options	5.74		(966,692)
Balance as of December 31, 2022	$	10.57	5,350,600	0.73
Exercisable as of December 31, 2022	$	11.48	3,867,887	0.66

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.

The following table summarizes stock options outstanding:


	Options outstanding as of December 31,
	2023	2022	2021
2020 Omnibus Plan	702,264	2,788,947	2,900,000
2018 Stock Option Plan	1,400,937	1,422,069	1,550,074
2015 Stock Option Plan	—	1,139,584	4,489,256
Total stock options outstanding	2,103,201	5,350,600	8,939,330

Fair Value of Options Issued

The fair value of the options issued during the year was determined using the Black-Scholes option pricing model, using the following inputs:


	2023	2022
Share price at grant date (per share)	C$2.96	C$4.20
Exercise price (per option)	C$2.96	C$4.20
Risk-free interest rate(i)	3.22%	3.14%
Expected life of options (in years)(i)	7	7
Expected annualized volatility(i)	73%	73%
Expected dividend yield	—	—
Weighted average Black-Scholes value at grant date (per option)	C$2.07	C$2.94
Forfeiture rate	—	—

Summary of Restricted Share Units Activity

The following is a summary of the changes in RSUs:


	Weighted average grant date fair value (C$)(iii)		Number of RSUs
Balance as of January 1, 2023	$	4.63	5,725,470
Granted(i)	2.64		3,292,586
Vested and issued	5.00		(1,041,097)
Cancellation and forfeitures	3.60		(595,418)
Balance as of December 31, 2023	$	3.77	7,381,541


	Weighted average grant date fair value (C$)(iii)		Number of RSUs
Balance as of January 1, 2022	$	9.22	1,225,870
Granted(i)(ii)	4.27		6,140,492
Vested and issued	7.40		(1,151,292)
Cancellation and forfeitures	5.08		(489,600)
Balance as of December 31, 2022	$	4.63	5,725,470

(iii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

Summary of Changes in Warrants and DSUs

The following is a summary of the changes in DSUs:


	Financial liability		Number of DSUs
Balance as of January 1, 2023	$	674	265,732
Granting and vesting of DSUs	450		255,947

Gain on revaluation	(32)		—
Balance as of December 31, 2023	$	1,092	521,679


	Financial liability		Number of DSUs
Balance as of January 1, 2022	$	408	104,442
Granting and vesting of DSUs	443		161,290

Loss on revaluation	(177)		—
Balance as of December 31, 2022	$	674	265,732

Summary of Liability-Classified Awards


	Financial liability
Balance as of January 1, 2022	$	—
Grants	597
Transfers to equity awards	(597)

Balance as of December 31, 2022	$	—

Discontinued Operations - Revenue by Major Product Category (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,029	$ 5,155	$ 9,874
Cannabis extracts
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,029	$ 5,155	$ 9,874

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 13,066	$ 14,594
Increase (decrease)	(1,528)	(662)
Foreign exchange effect	251	(866)
Ending balance	11,789	13,066	$ 14,594
Financing receivable, credit loss, expense, including transferred into investment		(1,528)	(662)
GrowCo Credit Facility \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	12,455	14,089
Increase (decrease)	(1,542)	(827)	(12,748)
Foreign exchange effect	263	(807)
Ending balance	11,176	12,455	14,089
Mucci Promissory Note \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	89	90
Increase (decrease)	(2)	4
Foreign exchange effect	2	(5)
Ending balance	89	89	90
Cannasoul Collaboration Loan \| Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	522	415
Increase (decrease)	16	161
Foreign exchange effect	(14)	(54)
Ending balance	$ 524	$ 522	$ 415

- Definition

Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.

+ References + Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a)Commitments R&D commitments On September 4, 2018, the Company announced an R&D partnership with Ginkgo to develop scalable and consistent production of a variety of certain common and lesser-known cannabinoids. As part of this partnership, Cronos agreed to issue up to 14,674,903 common shares of the Company (aggregate value of approximately $100,000 as of July 17, 2018 assuming all milestones are met, collectively the “Ginkgo Equity Milestones”) in tranches and $22,000 in cash subject to Ginkgo’s achievement of certain milestones and to fund certain R&D expenses, including foundry access fees. During the years ended December 31, 2022 and December 31, 2021, 4,157,888 shares and 2,934,980 shares, respectively, of the Company’s common stock were issued in conjunction with this partnership. No shares were issued for the year ended December 31, 2023. Other commitments On February 18, 2019, the Company entered into an agreement with a wholly owned subsidiary of Altria (which agreement was subsequently amended and restated to substitute Altria Pinnacle as a party thereto), to receive strategic advisory and project management services from Altria Pinnacle (the “Services Agreement”). Pursuant to the Services Agreement, the Company will pay Altria Pinnacle a monthly fee equal to the product of 105% and the sum of: (i) all costs directly associated with the services incurred during the monthly period, and (ii) a reasonable and appropriate allocation of indirect costs incurred during the monthly period. The Company will also pay all third-party direct charges incurred during the monthly period in connection with the services, including any reasonable and documented costs, fees and expenses associated with obtaining any consent, license or permit. The Services Agreement will remain in effect until terminated by either party. See Note 15 “Related Party Transactions.” (b)Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its consolidated financial condition but could be material to its results of operations for any particular reporting period depending, in part, on its results for that period. (i)Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and former Chief Financial Officer. The court consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5, promulgated thereunder, against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. The defendants moved to dismiss on February 8, 2021. On November 17, 2023, the court entered an order granting the motion and dismissed the case with prejudice. On December 1, 2023, the shareholder plaintiffs sought reconsideration of the dismissal, requesting that the court instead dismiss the action without prejudice and permit the plaintiffs to seek leave to further amend the complaint. The reconsideration motion is pending. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim named (i) the Company, (ii) its Chief Executive Officer, (iii) former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleged breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleged that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim did not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court. On April 11, 2023, the plaintiff filed a Fresh as Amended Statement of Claim, which reflected the dismissal of the defendants for which an appeal was not sought, the removal of the claims for oppression under the Ontario Business Corporations Act and common law misrepresentation, as well as shortening the proposed class period. On October 10, 2023, the Superior Court certified the action on behalf of a class of persons or entities who acquired shares in the secondary market, including on the TSX and Nasdaq, during the period from May 9, 2019 to March 30, 2020, other than certain excluded persons. (ii)Regulatory Settlements On October 24, 2022, the Company announced regulatory settlements as follows: SEC Settlement On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933 (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the Restatements. The Company agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposed of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount. The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years. OSC Settlement On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the Ontario Securities Commission (the “OSC”), resolving the Restatements. Pursuant to the terms of the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Ontario Securities Act to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. (iii)Litigation and regulatory inquiries relating to marketing, distribution, import and sale of products On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million. The Cronos Israel defendants moved to dismiss the action on August 13, 2023. On January 18, 2024, the Company was notified that the Trade Levies Commissioner of the Israel Ministry of Economy and Industry initiated a public investigation of alleged dumping of medical cannabis imports from Canada into Israel. The Company is responding to requests for information from the Ministry. The Company cannot predict the outcome of the investigation. We expect litigation and regulatory proceedings relating to the marketing, distribution, import and sale of our products to increase.

Goodwill and Intangible Assets, net (Tables)

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill is comprised of the following items:


	As of December 31, 2023
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,057	$	—	$	1,057
	$	1,057	$	—	$	1,057


	As of December 31, 2022
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,033	$	—	$	1,033
	$	1,033	$	—	$	1,033

Schedule of Finite-Lived Intangible Assets

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities

Intangible assets, net are comprised of the following items:


		As of December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078


		As of December 31, 2022
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,037		$	(2,388)		$	(76)		$	3,573
Health Canada licenses		8,269			(1,771)			(6,498)			—
Ginkgo exclusive licenses		27,676			(1,854)			(4,434)			21,388
Israeli codes(i)		292			(49)			—			243
Total definite-lived intangible assets		42,274			(6,062)			(11,008)			25,204
Lord Jones® brand		64,000						(62,500)			1,500
Trademarks		142						(142)			—
Total intangible assets		$	106,416		$	(6,062)		$	(73,650)		$	26,704

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Accumulated impairment charges on intangible assets, net consist of:


	As of January 1, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of January 1, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)


	As of January 1, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2021
Software	$	—	$	(4)	$	—	$	(4)
Health Canada licenses	(1,053)		(5,951)		94		(6,910)
Ginkgo exclusive licenses	—		(4,792)		40		(4,752)
Lord Jones® brand	(5,000)		(57,500)		—		(62,500)
Trademarks	—		(142)		—		(142)
	$	(6,053)	$	(68,389)	$	134	$	(74,308)

Schedule of Indefinite-Lived Intangible Assets

Intangible assets, net are comprised of the following items:


		As of December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078


		As of December 31, 2022
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,037		$	(2,388)		$	(76)		$	3,573
Health Canada licenses		8,269			(1,771)			(6,498)			—
Ginkgo exclusive licenses		27,676			(1,854)			(4,434)			21,388
Israeli codes(i)		292			(49)			—			243
Total definite-lived intangible assets		42,274			(6,062)			(11,008)			25,204
Lord Jones® brand		64,000						(62,500)			1,500
Trademarks		142						(142)			—
Total intangible assets		$	106,416		$	(6,062)		$	(73,650)		$	26,704

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Accumulated impairment charges on intangible assets, net consist of:


	As of January 1, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of January 1, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)


	As of January 1, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2021
Software	$	—	$	(4)	$	—	$	(4)
Health Canada licenses	(1,053)		(5,951)		94		(6,910)
Ginkgo exclusive licenses	—		(4,792)		40		(4,752)
Lord Jones® brand	(5,000)		(57,500)		—		(62,500)
Trademarks	—		(142)		—		(142)
	$	(6,053)	$	(68,389)	$	134	$	(74,308)

Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets

The estimated future amortization of definite-lived intangible assets is as follows:


	As of December 31, 2023
2024	$	3,365
2025	3,020
2026	2,498
2027	2,297
2028	2,156
Thereafter	6,242
	$	19,578

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Investments - Schedule of Variable Interest Entities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Other Net Assets (Liabilities)	$ 44,306	$ 46,013
Maximum Exposure to Loss	$ 19,488	$ 18,755
Cronos GrowCo
Variable Interest Entity [Line Items]
Ownership interest	50.00%	50.00%
Cronos GrowCo \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Other Net Assets (Liabilities)	$ 44,306	$ 46,013
Maximum Exposure to Loss	$ 19,488	$ 18,755

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Share-based Compensation - Restricted Share Units Narrative (Details)	12 Months Ended
	Dec. 31, 2023
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Goodwill and Intangible Assets, net

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, net

(a)Goodwill

Goodwill is comprised of the following items:


	As of December 31, 2023
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,057	$	—	$	1,057
	$	1,057	$	—	$	1,057


	As of December 31, 2022
	Cost		Accumulated impairment charges		Net
Peace Naturals	$	1,033	$	—	$	1,033
	$	1,033	$	—	$	1,033

(b)Intangible assets, net

Intangible assets, net are comprised of the following items:


		As of December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078


		As of December 31, 2022
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,037		$	(2,388)		$	(76)		$	3,573
Health Canada licenses		8,269			(1,771)			(6,498)			—
Ginkgo exclusive licenses		27,676			(1,854)			(4,434)			21,388
Israeli codes(i)		292			(49)			—			243
Total definite-lived intangible assets		42,274			(6,062)			(11,008)			25,204
Lord Jones® brand		64,000						(62,500)			1,500
Trademarks		142						(142)			—
Total intangible assets		$	106,416		$	(6,062)		$	(73,650)		$	26,704

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Ginkgo Exclusive Licenses

CBGA

In August 2021, the Company achieved the final productivity target in respect of cannabigerolic acid (“CBGA”), under the Ginkgo Collaboration Agreement. As a result, on August 21, 2021, the Company issued 1,467,490 common shares at a share price of C$7.90 for total consideration given of C$11,593 ($9,042) to Ginkgo for the achievement of commercialization and productivity milestones for CBGA. The estimated fair value of the exclusive license for CBGA (the “CBGA Exclusive License”) was $7,300 determined using a variation of the income approach called the relief-from-royalty method, which requires an estimate or forecast of the expected future cash flows. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of 10 years. The difference between the consideration paid to Ginkgo and the fair value of the exclusive license intangible asset of $1,784 was recognized as an impairment charge on the consolidated statements of net loss and comprehensive loss for the year ended December 31, 2021.

CBGVA

In November, 2021, the Company achieved the final productivity target in respect of cannabigerovarinic acid (“CBGVA”). As a result, on November 12, 2021, the Company issued 1,467,490 common shares at a share price of C$7.12 for total consideration given of C$10,449 ($8,150) to Ginkgo. The estimated fair value of the exclusive license for CBGVA (the “CBGVA Exclusive License”) was $5,300 determined using a variation of the income approach called the relief-from-royalty method, which requires an estimate or forecast of the expected future cash flows. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of 10 years. The difference between the consideration paid to Ginkgo and the fair value of the exclusive license intangible asset of $3,008 was recognized as an impairment charge on the consolidated statements of net loss and comprehensive loss for the year ended December 31, 2021.

THCVA

In June 2022, the Company achieved the final productivity target in respect of tetrahydrocannabivaric acid (“THCVA”) under the Ginkgo Collaboration Agreement. As a result, the Company issued 2,201,236 common shares at a share price of C$3.47, and made a cash payment of $600, for total consideration of C$8,412 ($6,522) to Ginkgo. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of 10 years.

CBCA

In November 2022, the Company achieved the early commercialization milestone in respect of cannabichromenic acid (“CBCA”) under the Ginkgo Collaboration Agreement. As a result, the Company issued 489,163 common shares at a share price of C$4.11 for total consideration of C$2,010 ($1,473) to Ginkgo. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of 10 years.

CBCVA

In December 2022, the Company achieved the final productivity target in respect of cannabichromevarinic acid (“CBCVA”) under the Ginkgo Collaboration Agreement. As a result, the Company issued 1,467,490 common shares at a share price of C$3.44 for total consideration of C$5,048 ($3,724) to Ginkgo. In December 2023, the Company determined that it had no immediate plans to monetize CBCVA and, therefore, recognized $3,366 in impairment charges on the consolidated statements of net loss and comprehensive loss for the year ended December 31, 2023, which resulted in a $nil carrying value of the intangible asset as of December 31, 2023.

For the years ended December 31, 2023, 2022 and 2021, the aggregate amortization expense on intangible assets was $3,514, $2,751 and $1,800, respectively, and was included in depreciation and amortization in operating expenses on the consolidated statements of net loss and comprehensive loss.

The estimated future amortization of definite-lived intangible assets is as follows:


	As of December 31, 2023
2024	$	3,365
2025	3,020
2026	2,498
2027	2,297
2028	2,156
Thereafter	6,242
	$	19,578

Impairment of Intangible Assets

Accumulated impairment charges on intangible assets, net consist of:


	As of January 1, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of January 1, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)


	As of January 1, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2021
Software	$	—	$	(4)	$	—	$	(4)
Health Canada licenses	(1,053)		(5,951)		94		(6,910)
Ginkgo exclusive licenses	—		(4,792)		40		(4,752)
Lord Jones® brand	(5,000)		(57,500)		—		(62,500)
Trademarks	—		(142)		—		(142)
	$	(6,053)	$	(68,389)	$	134	$	(74,308)

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Pre-emptive Rights \| Share price at valuation date (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.77	3.44
Pre-emptive Rights \| Subscription price (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.60	0.73
Pre-emptive Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0399	0.0414
Pre-emptive Rights \| Weighted Average \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 9 months	3 months
Top-up Rights \| Share price at valuation date (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.77	3.44
Top-up Rights \| Subscription price (in canadian dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.58	0.73
Top-up Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0476	0.0428
Top-up Rights \| Weighted Average \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	7 months 6 days	7 months 2 days
Pre-Emptive Rights and Top-Up Rights \| Minimum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0399	0.0381
Pre-Emptive Rights and Top-Up Rights \| Minimum \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	6 months	3 months
Pre-Emptive Rights and Top-Up Rights \| Maximum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0482	0.0437
Pre-Emptive Rights and Top-Up Rights \| Maximum \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 9 months	2 years 9 months

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Schedule of Consolidated Entities

The Company consolidates the financial results of the following entities, which the Company controls but does not wholly own:

Subsidiaries

Jurisdiction of incorporation

Incorporation date

Ownership interest (ii)

Cronos Israel G.S. Cultivation Ltd.(i)

Israel

February 4, 2018

70%

Cronos Israel G.S. Manufacturing Ltd.(i)

Israel

September 4, 2018

90%

Cronos Israel G.S. Store Ltd.(i)

Israel

June 28, 2018

90%

Cronos Israel G.S. Pharmacy Ltd.(i)

Israel

February 15, 2018

90%

(i)These Israeli entities are collectively referred to as “Cronos Israel.”

(ii)“Ownership interest” is defined as the proportionate share of net income to which the Company is entitled; equity interest may differ from ownership interest as described herein.

Schedule of Property, Plant and Equipment, Useful Lives

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

Rate

Building and leasehold improvements

15 to 20 years

Machinery and equipment

5 to 7 years

Furniture and fixtures

5 years

Property, plant and equipment, net consisted of the following:


	As of December 31,
		2023		2022
Cost
Land		$	2,764	$	2,556
Building and leasehold improvements		168,498		177,095
Machinery and equipment		21,322		19,130
Furniture and fixtures		3,385		5,345
Construction in progress		3,269		841
Less: accumulated depreciation		(30,707)		(35,347)
Less: accumulated impairment charges		(109,063)		(109,063)
Property, plant and equipment, net		$	59,468	$	60,557

Schedule of Intangible Assets Amortization Methods and Rates

Intangible assets with definite useful lives are amortized over their estimated useful lives using the following methods and rates:


	Method	Rate
Software	Straight-line	5 years
Health Canada licenses	Straight-line	Useful life of corresponding facilities
Ginkgo exclusive licenses	Straight-line	10 years
Israeli codes(i)	Straight-line	Useful life of corresponding facilities

Intangible assets, net are comprised of the following items:


		As of December 31, 2023
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,860		$	(3,508)		$	(78)		$	3,274
Health Canada licenses		8,463			(1,813)			(6,650)			—
Ginkgo exclusive licenses		28,326			(4,276)			(7,968)			16,082
Israeli codes(i)		284			(62)			—			222
Total definite-lived intangible assets		43,933			(9,659)			(14,696)			19,578
Lord Jones® brand		64,000			—			(62,500)			1,500
Trademarks		142			—			(142)			—
Total intangible assets		$	108,075		$	(9,659)		$	(77,338)		$	21,078


		As of December 31, 2022
	Cost			Accumulated amortization			Accumulated impairment charges			Net
Software		$	6,037		$	(2,388)		$	(76)		$	3,573
Health Canada licenses		8,269			(1,771)			(6,498)			—
Ginkgo exclusive licenses		27,676			(1,854)			(4,434)			21,388
Israeli codes(i)		292			(49)			—			243
Total definite-lived intangible assets		42,274			(6,062)			(11,008)			25,204
Lord Jones® brand		64,000						(62,500)			1,500
Trademarks		142						(142)			—
Total intangible assets		$	106,416		$	(6,062)		$	(73,650)		$	26,704

(i) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Accumulated impairment charges on intangible assets, net consist of:


	As of January 1, 2023		Impairment charges		Foreign exchange effect		As of December 31, 2023
Software	$	(76)	$	—	$	(2)	$	(78)
Health Canada licenses	(6,498)		—		(152)		(6,650)
Ginkgo exclusive licenses	(4,434)		(3,366)		(168)		(7,968)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(73,650)	$	(3,366)	$	(322)	$	(77,338)


	As of January 1, 2022		Impairment charges		Foreign exchange effect		As of December 31, 2022
Software	$	(4)	$	(76)	$	4	$	(76)
Health Canada licenses	(6,910)		—		412		(6,498)
Ginkgo exclusive licenses	(4,752)		—		318		(4,434)
Lord Jones® brand	(62,500)		—		—		(62,500)
Trademarks	(142)		—		—		(142)
	$	(74,308)	$	(76)	$	734	$	(73,650)


	As of January 1, 2021		Impairment charges		Foreign exchange effect		As of December 31, 2021
Software	$	—	$	(4)	$	—	$	(4)
Health Canada licenses	(1,053)		(5,951)		94		(6,910)
Ginkgo exclusive licenses	—		(4,792)		40		(4,752)
Lord Jones® brand	(5,000)		(57,500)		—		(62,500)
Trademarks	—		(142)		—		(142)
	$	(6,053)	$	(68,389)	$	134	$	(74,308)

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:


	As of December 31,
	2023		2022
Accrued payroll and related expenses	$	8,970	$	11,492
Accrued professional fees	2,525		2,414
Accrued taxes	11,695		4,132
Other accrued expenses	4,546		4,230
Total accrued liabilities	$	27,736	$	22,268

Revenue from External Customers by Products and Services

The following table presents the Company's revenue by major product category for continuing operations:


	Year ended December 31,
	2023		2022		2021
Cannabis flower	$	62,070	$	63,593	$	55,194
Cannabis extracts	24,569		22,522		8,807
Other	602		634		560
Net revenue	$	87,241	$	86,749	$	64,561

Schedule of Revenue from External Customers by Geographic Areas

Net revenue attributed to a geographic region based on the location of the customer was as follows:


	Year ended December 31,
	2023		2022		2021
Canada	$	64,702	$	56,233	$	50,294
Israel	21,134		30,516		13,376

Other countries	1,405		—		891
Net revenue	$	87,241	$	86,749	$	64,561

Loans Receivable, net - Schedule of Loan Receivable (Details) ₪ in Thousands	12 Months Ended					52 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2023 ILS (₪)	Dec. 31, 2022 ILS (₪)	Sep. 30, 2022	Aug. 31, 2021 CAD ($)	Aug. 23, 2019 CAD ($)	Jun. 28, 2019 USD ($)	Jun. 28, 2019 CAD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable	$ 5,541,000		$ 8,890,000			$ 5,541,000
Total long-term portion of loans receivable	69,036,000		72,345,000			69,036,000
Increase in the allowance	(1,528,000)		(662,000)
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Accrued interest	507,000		4,463,000			507,000
Total current portion of loans receivable	5,541,000		8,890,000			5,541,000
Add: Long-term portion of accrued interest	248,000		172,000			248,000
Total long-term portion of loans receivable	69,036,000		72,345,000			69,036,000
Total loans receivable	74,577,000		81,235,000			74,577,000
GrowCo Credit Facility \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	5,034,000		4,427,000			5,034,000
Long term portion of loans receivable, before accrued interest	53,638,000		56,898,000			53,638,000
Face amount											$ 105,000,000	$ 100,000,000
Increase in the allowance	(1,542,000)		(827,000)		$ (12,748,000)
Draw downs	78,532,000	$ 104,000,000	76,730,000	$ 104,000,000
Proceeds from loans receivable	5,612,000	7,500,000	3,073,000	4,000,000		8,685,000	$ 11,500,000
Interest received	10,287,000	13,462,000	5,209,000	$ 7,060,000		15,496,000	$ 20,522,000
Mucci Promissory Note \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	13,379,000		13,438,000			13,379,000
Face amount													$ 12,063,000	$ 16,350,000
Increase in the allowance	(2,000)		4,000
Interest received	897,000	1,187,000
Stated interest rate													3.95%	3.95%
Proceeds from repayment on loan outstanding principal	425,000	$ 563,000
Mucci Promissory Note \| Loans Receivable \| Canadian Prime Rate
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans receivable, basis spread on variable rate										1.25%
Cannasoul Collaboration Loan \| Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	1,771,000		1,837,000			1,771,000
Increase in the allowance	16,000		161,000
Cannasoul Collaboration Loan \| Loans Receivable \| Establishment of a Commercial Cannabis Analytical Testing Laboratoy \| Cannasoul Analytics Ltd. \| Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received	$ 2,294,000		$ 2,359,000			$ 2,294,000		₪ 8,297	₪ 8,297

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2023

Risks and Uncertainties [Abstract]

Schedule of Fair Value of Assets on Recurring Basis


	As of December 31, 2023
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	669,291	$	—	$	—	$	669,291
Short-term investments	192,237		—		—		192,237
Other investments(i)	9,601		—		—		9,601
Derivative liabilities	—		—		102		102


	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	764,644	$	—	$	—	$	764,644
Short-term investments	113,077		—		—		113,077
Other investments(i)	21,993		—		—		21,993
Derivative liabilities	—		—		15		15

Schedule of Fair Value of Assets on Nonrecurring Basis


	As of December 31, 2023
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	25,650	25,650


	As of December 31, 2022
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	49,000	49,000

Financial Instruments - Interest Rate Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Investments, All Other Investments [Abstract]
Effect of 10% change in interest rate on interest income, net	$ 5,400
Interest income, net	$ 51,235	$ 22,514	$ 9,068
Impact of change in average variable rate, percent	1.45%	3.50%

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2023 segment	Mar. 31, 2023 segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Impairment Of Intangible Asset, Finite-Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag			consolidated statements of net loss and comprehensive loss
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Net Derivative Asset (Liability) Gain (Loss), Statement Of Income, Extensible List, Not Disclosed Flag			consolidated statements of net loss
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Net Derivative, Asset (Liability) Gain (Loss), Statement Of Other Comprehensive Income, Extensible List, Not Disclosed Flag			comprehensive loss
Advertising costs \| $			$ 1,382	$ 889	$ 2,229
Number of reportable segments	1	2
Number of operating segments	1

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Related Party Transactions

The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”):


	Year ended December 31,
	2023		2022		2021
Altria Pinnacle – expense	$	—	$	—	$	436

The Company made the following purchases of cannabis products from Cronos GrowCo:


	Year ended December 31,
	2023		2022		2021
Cronos GrowCo – purchases	$	21,335	$	18,144	$	4,820

Commitments and Contingencies - Contingencies (Details) $ in Thousands, ₪ in Millions	Apr. 17, 2023 ILS (₪) defendant	Oct. 24, 2022 CAD ($)	Mar. 12, 2020 shareholder complaint
U.S. District Court of Eastern District of New York Vs. Cronos \| Pending Litigation
Loss Contingencies [Line Items]
Number of alleged shareholders \| shareholder			2
Number of putative class action complaints \| complaint			2
OSC Settlement \| Settled Litigation
Loss Contingencies [Line Items]
Payments for legal settlements \| $		$ 1,340
Green Leaf Vs. Cronos
Loss Contingencies [Line Items]
Number of defendants	26
Damages sought \| ₪	₪ 420
Green Leaf Vs. Cronos \| Cronos Group, Inc.
Loss Contingencies [Line Items]
Number of defendants	3

Share-based Compensation - Liability-Classified Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Grants	$ 8,756	$ 15,008	$ 9,844
Liability Classified Awards
Share-Based Payment Arrangement [Abstract]
Balance at beginning of period	0	0
Grants	$ 0	597	0
Transfers to equity awards		(597)
Balance at end of period		$ 0	$ 0

Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2024	$ 3,365
2025	3,020
2026	2,498
2027	2,297
2028	2,156
Thereafter	6,242
Net	$ 19,578	$ 25,204

Loans Receivable, net

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

Loans Receivable, net

Loans receivable, net consists of the following:


	As of December 31,
	2023		2022


GrowCo Credit Facility	$	5,034	$	4,427
Add: Accrued interest	507		4,463
Total current portion of loans receivable	5,541		8,890
GrowCo Credit Facility	53,638		56,898
Mucci Promissory Note	13,379		13,438
Cannasoul Collaboration Loan	1,771		1,837
Add: Long-term portion of accrued interest	248		172
Total long-term portion of loans receivable	69,036		72,345
Total loans receivable	$	74,577	$	81,235

Cronos GrowCo Credit Facility

On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Credit Facility”). The GrowCo Credit Facility is secured by substantially all present and after-acquired personal and real property of Cronos GrowCo. In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$105,000. As a result of the increase in the aggregate principal amount of the GrowCo Credit Facility and lower than expected sales forecasts from Cronos GrowCo, the Company revalued its allowance for credit loss on the GrowCo Credit Facility resulting in an increase in the allowance of $12,748, which was recorded in general and administrative expenses on the consolidated statements of net loss and comprehensive loss for the year ended December 31, 2021. As of both December 31, 2023 and 2022, Cronos GrowCo had drawn C$104,000 ($78,532 and $76,730), respectively, from the GrowCo Credit Facility. For the years ended December 31, 2023 and 2022, Cronos GrowCo repaid C$7,500 ($5,612) and C$4,000 ($3,073) in principal and C$13,462 ($10,287) and C$7,060 ($5,209) in interest, respectively. As of December 31, 2023, Cronos GrowCo had repaid, in the aggregate, C$11,500 ($8,685) and C$20,522 ($15,496) in principal and interest, respectively, under the terms of the GrowCo Credit Facility.

Mucci Promissory Note

On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$16,350 (approximately $12,063) with Mucci. The Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023.

Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. Prior to 2023, there were no repayments of principal or interest on the Mucci Promissory Note. For the year ended December 31, 2023, Mucci repaid C$563 ($425) in principal and C$1,187 ($897) in interest related to the Mucci Promissory Note.

Cannasoul Collaboration Loan

As of both December 31, 2023 and 2022, CLS has received ILS 8,297 (approximately $2,294 and $2,359, respectively), from the Cannasoul Collaboration Loan. See Note 4 “Investments” for further information regarding the Cannasoul Collaboration Loan.

Expected credit loss allowances on the Company’s long-term financial assets were comprised of the following items:


	As of January 1, 2023		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2023
GrowCo Credit Facility	$	12,455	$	(1,542)	$	263	$	11,176

Mucci Promissory Note	89		(2)		2		89
Cannasoul Collaboration Loan	522		16		(14)		524
	$	13,066	$	(1,528)	$	251	$	11,789


	As of January 1, 2022		Increase (decrease)(i)		Foreign exchange effect		As of December 31, 2022
GrowCo Credit Facility	$	14,089	$	(827)	$	(807)	$	12,455

Mucci Promissory Note	90		4		(5)		89
Cannasoul Collaboration Loan	415		161		(54)		522
	$	14,594	$	(662)	$	(866)	$	13,066

Related Party Transactions - Schedule of Related Party Transactions (Details) - Related Party - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consulting Services
Related Party Transaction [Line Items]
Expense	$ 0	$ 0	$ 436
Cannabis Purchases
Related Party Transaction [Line Items]
Purchases	$ 21,335	$ 18,144	$ 4,820

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred assets:
Tax loss carryforwards	$ 111,516	$ 98,074
Interest expense carryforwards	2,688	2,533
Deferred financing costs	0	1,311
Share issuance cost	0	196
Finance lease obligation	519	690
Plant and equipment	36,697	37,662
Investment	19,745	13,359
Intangible asset	37,203	53,365
Inventory	556	1,287
Reserve	2,430	2,972
Unrealized foreign exchange	275	0
R&D investment tax credits	567	293
Other	4,271	3,099
Total deferred tax assets	216,467	214,841
Less valuation allowance	(216,241)	(214,199)
Net deferred tax assets	226	642
Deferred tax liabilities:
Right-of-use assets	(181)	(365)
Unrealized foreign exchange	0	(84)
Total deferred tax liabilities	(181)	(449)
Net deferred tax assets	$ 45	$ 193

Loss per Share

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Loss per Share

Basic and diluted earnings (loss) per share from continued and discontinued operations are calculated as follows:


	Year ended December 31,
	2023		2022		2021
Basic loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$	(69,849)	$	(155,178)	$	(126,982)
Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share(i)	380,964,739		376,961,797		370,390,965
Basic loss from continuing operations per share	$	(0.18)	$	(0.41)	$	(0.34)
Diluted loss per share from continuing operations	$	(0.18)	$	(0.41)	$	(0.34)

Loss from discontinued operations attributable to the shareholders of Cronos Group	$	(4,114)	$	(13,556)	$	(269,125)
Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share(i)	380,964,739		376,961,797		370,390,965
Basic loss from discontinued operations per share	$	(0.01)	$	(0.04)	$	(0.73)
Diluted loss from discontinued operations per share	$	(0.01)	$	(0.04)	$	(0.73)

Total securities of 25,426,119, 112,612,579 and 125,195,001 were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, 2022 and 2021, respectively, because the effect would be anti-dilutive.

Related Party Transactions

12 Months Ended

Dec. 31, 2023

Related Party Transactions

(a)Altria

On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company. As of December 31, 2023, Altria beneficially held an approximately 41.1% ownership interest in the Company (calculated on a non-diluted basis).

The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”):


	Year ended December 31,
	2023		2022		2021
Altria Pinnacle – expense	$	—	$	—	$	436

There were no amounts payable related to the consulting services with Altria Pinnacle as of December 31, 2023 and 2022.

Refer to Note 9 “Derivative Liabilities” for further information on the derivative liabilities related to the Altria Investment.

(b)Cronos GrowCo

The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 4 “Investments” for further discussion.

The Company made the following purchases of cannabis products from Cronos GrowCo:


	Year ended December 31,
	2023		2022		2021
Cronos GrowCo – purchases	$	21,335	$	18,144	$	4,820

The Company’s outstanding payable balance to Cronos GrowCo was $2,267 and $2,519 as of December 31, 2023 and December 31, 2022, respectively.

During the third quarter of 2023, the Company, as supplier, entered into a cannabis germplasm supply agreement with Cronos GrowCo as buyer. During 2023, the Company received proceeds of $1,114 in relation to this agreement.

Also during 2023, the Company sold certain held for sale assets with carrying value of $332 and certain other previously expensed assets with a zero net book value to Cronos GrowCo for total proceeds of $761 and recognized a $436 gain in Other, net in the consolidated statements of net loss and comprehensive loss.

Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Credit Facility. See additional information in Note 5 “Loans Receivable, net”.

(c)Vendor Agreement

In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another vendor whose chief executive officer is an immediate family member of an executive of the Company. The Company purchased $2,310 and $645 of products and services under this subcontracted agreement for the years ended December 31, 2023 and December 31, 2022, respectively. The company had $28 in outstanding accounts payables related to the subcontracted agreement as of December 31, 2023 and no outstanding accounts payable related to the subcontracted agreement as of December 31, 2022.

In November 2023, the Company negotiated a direct contract with the related-party vendor. During the year ended 2023, the Company purchased $42 of products and services directly from the related-party vendor and had $11 in outstanding accounts payable to the vendor as of December 31, 2023.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Financial Instruments - Schedule of Fair Value of Assets on Nonrecurring Basis (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 14, 2021	Dec. 31, 2023	Dec. 31, 2022	Feb. 28, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 35,251	$ 70,993		$ 118,392
Sale of stock, price per share (in dollars per share)	$ 0.0001
Percentage of ownership after transaction	10.50%
Payments to acquire other investments	$ 110,392
Pharmacann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ownership interest		5.90%	6.30%	6.40%
Pharmacann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	473,787
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 25,650	$ 49,000
Level 1 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		0	0
Level 2 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		0	0
Level 3 \| Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 25,650	$ 49,000

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments [Roll Forward]
Beginning balance	$ 15	$ 14,375
Loss (gain) on revaluation	85	(14,060)
Foreign exchange effect	2	(300)
Ending balance	102	15
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance	0	13,720
Loss (gain) on revaluation		(13,431)
Foreign exchange effect		(289)
Ending balance		0
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	0	180
Loss (gain) on revaluation	100	(179)
Foreign exchange effect	2	(1)
Ending balance	102	0
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	15	475
Loss (gain) on revaluation	(15)	(450)
Foreign exchange effect	0	(10)
Ending balance	$ 0	$ 15

Share-based Compensation - Summary of the Changes in Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 10.57	$ 7.75
Issuance of options (in dollars per share)	2.96	4.20
Exercised (in dollars per share)		2.79
Cancellation, forfeiture and expiry of options (in dollars per share)	7.75	5.74
Balance at end of period (in dollars per share)	14.50	10.57	$ 7.75
Exercisable (in dollars per share)	$ 15.89	$ 11.48
Number of options
Balance at beginning of period (in shares)	5,350,600	8,939,330
Issuance of options (in shares)	188,317	113,947
Exercised (in shares)		(2,735,985)
Cancellation of options (in shares)	(3,435,716)	(966,692)
Balance at end of period (in shares)	2,103,201	5,350,600	8,939,330
Exercisable (in shares)	1,864,732	3,867,887
Weighted average remaining contractual term (years)
Outstanding	1 year 10 months 2 days	8 months 23 days	2 years 8 months 12 days
Exercisable	1 year 3 months 14 days	7 months 28 days

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Intangible Assets Amortization Methods and Rates (Details)	Dec. 31, 2023
Software
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years

Inventory, net

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventory, net

Inventory, net is comprised of the following items:


	As of December 31,
	2023		2022
Raw materials	$	4,795	$	7,421
Work-in-progress	10,593		15,646
Finished goods	14,819		13,503
Supplies and consumables	288		989
Total	$	30,495	$	37,559

Discontinued Operations - Lease Information Associated with Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lease cost
Operating lease cost	$ 685	$ 1,107	$ 1,693
Short-term lease cost	0	0	10
Total lease cost	685	1,107	1,703
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	1,124	1,441	1,706
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	$ 0	$ 0	$ 0
Weighted-average remaining lease term (years) – operating leases	3 years 7 months 6 days	4 years 3 months 18 days	4 years 8 months 12 days
Weighted-average discount rate – operating leases	7.62%	7.39%	7.62%
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Lease cost
Operating lease cost	$ 213	$ 1,102	$ 837
Short-term lease cost	0	0	0
Total lease cost	213	1,102	837
Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	525	1,050	752
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	$ 0	$ 443	$ 3,277
Weighted-average remaining lease term (years) – operating leases	0 years	1 year	3 years 9 months 18 days
Weighted-average discount rate – operating leases	0.00%	5.62%	7.65%

Derivative Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Reconciliation of Carrying Amounts

Reconciliations of the carrying amounts of the derivative liability are presented below:


	As of January 1, 2023		Loss (gain) on revaluation		Foreign exchange effect		As of December 31, 2023

Pre-emptive Rights	—		100		2		102
Top-up Rights	15		(15)		—		—
	$	15	$	85	$	2	$	102


	As of January 1, 2022		Gain on revaluation		Foreign exchange effect		As of December 31, 2022
Altria Warrant	$	13,720	$	(13,431)	$	(289)	$	—
Pre-emptive Rights	180		(179)		(1)		—
Top-up Rights	475		(450)		(10)		15
	$	14,375	$	(14,060)	$	(300)	$	15

Schedule of Fair Values of Derivative Liabilities

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:


	As of December 31, 2023
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$2.77	$2.77
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	3.99%	4.76%
Weight average expected life (in years)(ii)	1.75	0.60
Expected annualized volatility(iii)	60%	58%
Expected dividend yield	—%	—%


	As of December 31, 2022
	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	$3.44	$3.44
Subscription price (per share in C$)	$16.25	$16.25
Weighted average risk-free interest rate(i)	4.14%	4.28%
Weight average expected life (in years)(ii)	0.25	0.59
Expected annualized volatility(iii)	73%	73%
Expected dividend yield	—%	—%

(iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Property, Plant and Equipment, net - Schedule of Property, Plant & Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (30,707)	$ (35,347)
Less: accumulated impairment charges	(109,063)	(109,063)
Property, plant and equipment, net	59,468	60,557
Land
Property, Plant and Equipment [Line Items]
Cost	2,764	2,556
Building and leasehold improvements
Property, Plant and Equipment [Line Items]
Cost	168,498	177,095
Machinery and equipment
Property, Plant and Equipment [Line Items]
Cost	21,322	19,130
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Cost	3,385	5,345
Construction in progress
Property, Plant and Equipment [Line Items]
Cost	$ 3,269	$ 841

Income Taxes - Expense for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Current	$ (3,375)	$ 34,416	$ (471)
Deferred	145	(241)	40
Income tax expense (benefit), net	$ (3,230)	$ 34,175	$ (431)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

For financial reporting purposes, loss from continuing operations before income taxes includes the following components:


	Year ended December 31,
	2023		2022		2021
Loss before income taxes	$	(73,669)	$	(121,003)	$	(128,510)

The loss before income taxes above excludes losses from discontinued operations of $4,114, $13,556 and $269,125 for the years ended December 31, 2023, 2022 and 2021, respectively.

Income tax expense (benefit) consists of the following components:


	Year Ended December 31,
	2023		2022		2021
Current	$	(3,375)	$	34,416	$	(471)
Deferred	145		(241)		40
Total	$	(3,230)	$	34,175	$	(431)

As of December 31, 2023, 2022 and 2021, the Company’s current income taxes payable were $64, $32,956 and $105, respectively, related to current income tax expense. Included in other receivables as of December 31, 2023, 2022 and 2021 is $3,374, $40 and $543, respectively, related to current income tax benefits.

Income tax differs from that computed using the combined Canadian federal and provincial statutory income tax rate of 26.5%. Reconciliation of the expected income tax to the effective tax rate in continuing operations is as follows:


	Year ended December 31,
	2023			2022				2021
Loss before income taxes	$	(73,669)		$	(121,003)		$	$	(128,510)
Effective income tax rate	26.5		%	26.5		%		26.5		%
Expected income tax benefit	$	(19,522)		$	(32,066)			$	(34,055)

Non-taxable income (loss)	1,077			(2,140)				39
Non-deductible share-based compensation	525			1,198				1,667
Non-deductible expenses	459			836				53
Non-deductible transaction costs	351			1,625				2,917
Effect of provincial tax rate difference	(9)			(15)				(1)
Effect of tax rates outside of Canada	816			1,848				(1,869)
Effect of change in tax rates	4,601			11,041				—
Fair value gain (loss) on financial liabilities	23			(3,726)				(40,111)
Changes in valuation allowance	7,930			(10,466)				70,453
Capital gain on financial liabilities	106			66,193				—
Other	413			(153)				476
Income tax expense (benefit), net	$	(3,230)		$	34,175			$	(431)

The valuation allowance recorded against the loss on discontinued operations is not reflected in the effective tax rate reconciliation presented above for continuing operations.

For the year ended December 31, 2022, the Company realized a capital gain for tax purposes of $479,800 as a result of Altria’s irrevocable relinquishment of its warrant on December 16, 2022, resulting in an increase in the total income tax expense reported for the year ended December 31, 2022.

The following table summarizes the significant components of the Company’s deferred tax assets and liabilities:


	As of December 31,
	2023		2022
Deferred assets:
Tax loss carryforwards	$	111,516	$	98,074
Interest expense carryforwards	2,688		2,533
Deferred financing costs	—		1,311
Share issuance cost	—		196
Finance lease obligation	519		690
Plant and equipment	36,697		37,662
Investment	19,745		13,359
Intangible asset	37,203		53,365
Inventory	556		1,287
Reserve	2,430		2,972
Unrealized foreign exchange	275		—
R&D investment tax credits	567		293
Other	4,271		3,099
Total deferred tax assets	216,467		214,841
Less valuation allowance	(216,241)		(214,199)
Net deferred tax assets	226		642
Deferred tax liabilities:





Right-of-use assets	(181)		(365)
Unrealized foreign exchange	—		(84)
Total deferred tax liabilities	(181)		(449)
Net deferred tax asset (liability)(i)	$	45	$	193

(i)Net deferred tax asset (liability) is reported as Other assets within our consolidated balance sheet.

The realization of deferred tax assets is dependent on the Company’s generating sufficient taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the deferred tax assets that the Company determined did not meet the more-likely-than-not recognition threshold under U.S. GAAP.

As of December 31, 2023 and 2022, the Company’s valuation allowance was $216,241 and $214,199, respectively. The valuation allowance increased by $2,042 during the year ended December 31, 2023, and decreased by $10,577 during the year ended December 31, 2022. The increase in the valuation allowance during the year ended December 31, 2023, was primarily due to an increase in net operating loss carryforwards. The decrease in the valuation allowance during the year ended December 31, 2022, was primarily due to the recognition of a portion of deferred tax assets for which a valuation allowance was recorded in the prior year.

As of December 31, 2023, the Company had net operating losses in Canada, the U.S., and Israel available to offset future years’ taxable income of approximately $253,521, $144,219, $20,794, respectively. As of December 31, 2022, the Company had net operating losses in Canada, the U.S., and Israel available to offset future years’ taxable income of approximately $216,120, $134,593, and $18,739, respectively. The net operating losses in Canada will begin to expire, for purposes of carryforward, in fiscal year 2033. The net operating losses in the U.S. can be carried forward indefinitely for federal purposes. The net operating losses in Israel can be carried forward indefinitely.

Utilization of the net operating loss carryforwards may be subject to limitations under the tax laws applicable in each tax jurisdiction due to ownership changes that could occur in the future. These ownership changes could limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax expense. Due to the existence of the valuation allowance, limitations created by ownership changes, if any, will not impact the Company’s effective tax rate.

As of December 31, 2023, the Company has various scientific research and experimental development investment tax credit carryforwards of $683 related to Canadian operations, which, if not utilized, will begin to expire in 2041. Investment tax credits are recognized when realization of the tax credits is more likely than not.

The Company files federal income tax returns in Canada, Israel and the U.S. The Company has open tax years with the taxation jurisdictions. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and

regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenue and expense. As of December 31, 2023, Peace Naturals and Hortican Inc. are under examination with the Canadian Revenue Agency for tax years 2019 and 2020.


Jurisdiction						Open Years
Canada						2019 – 2023
United States						2020 – 2023
Israel						2020 – 2023

Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold may be recognized. There were no identified unrecognized tax benefits as of December 31, 2023 or December 31, 2022.

As of December 31, 2023 and 2022, deferred income taxes have not been provided for any undistributed earnings from operations outside of Canada. The foreign subsidiaries have accumulated losses and as such the amount of undistributed earnings upon which income taxes have not been provided is immaterial to these consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Schedule of Lease Cost and Other Information


	As of December 31,
	2023			2022			2021
Lease cost
Operating lease cost	$	685		$	1,107		$	1,693
Short-term lease cost	—			—			10
Total lease cost	$	685		$	1,107		$	1,703

Supplemental cash flow and other information
Operating cash flows - cash paid for operating lease obligations	$	1,124		$	1,441		$	1,706
Non-cash activity - right-of-use assets obtained in exchange for lease obligations	—			—			—

Weighted-average remaining lease term (years) – operating leases	3.6			4.3			4.7
Weighted-average discount rate – operating leases	7.62		%	7.39		%	7.62		%

Schedule of Future Minimum Lease Payments for Operating Leases

The following is a summary of the Company’s future minimum lease payments under operating leases for its premises due in future fiscal years:


	As of December 31, 2023
2024	$	1,132
2025	1,006
2026	247
2027	95
2028	95
Thereafter	412
Total lease payments	2,987
Less: imputed interest	(434)
Present value of lease liabilities	$	2,553